WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 14, Issue 13, 741-837. Research Article ISSN 2277–7105

REGULATORY REQUIREMENTS FOR DRUG, DEVICE AND BIOLOGICALS OFCOMBINATION PRODUCTS AS PER USFDA GUIDELINES

***[1]R. Lancyjenifer and [2]Dr. N. Senthil Kumar**

[1]M. Pharm, [2]Ph. D., Principal

The Tamil Nadu Dr. M. G. R Medical University, Chennai-32.

Article Received on
11 May 2025

Revised on 31 May 2025
Accepted on 21 June 2025

DOI: 10.20959/wjpr202513-37169

***Corresponding Author**
R. Lancyjenifer
M. Pharm, The Tamil Nadu Dr. M. G. R Medical University, Chennai-32.

ABSTRACT

Regulatory requirements for Drug, Device and Biologicals of Combination Products as Per USFDA Guidelines All healthcare products in the pharmaceutical industry are divided into three categories: drugs, devices, and biologics, and each is governed by its own regulatory authority. In the current scenario, the advancement of science and technology has led to the invention of innovative novel products in the healthcare system for better diagnosis and treatment of diseases. Advancement of these novel technologies has led to a blurring of traditional lines of separation between healthcare products, resulting in the existence of combination products. When opposed to individual products, combination products presenta host of regulatory and review issues. When opposed to single-entity products, combination products face a host of regulatory and review issues. In this thesis we have describe the regulations for registration of combination products in US and their regulatory considerations for identification, jurisdiction and review, premarket activities, applicability of Good Manufacturing Practices (GMPs) and post marketed requirements, e-CTD submission, clinical trial guidance document, and adverse event reporting, inspection and enforcement. Regulatory challenges and combination product requirements in accordance with FDA guidelines.

INTRODUCTION

1.1 Combination Product

Diagnostic and therapeutic products that incorporate medications, instruments, and/or biological properties are formulated as combined products. To obtain a significant numberof hybrid products for analysis as technical developments begin towards combine product categories and confuse the historical distinction boundaries between the FDA tends to center for Medicinal Items, consisting of a Center for Biological Evaluation and Research(CBER), the Center for Drug Evaluation and Research (CDER) as well as the Center for Devices and Radiological Health (CDRH). Since combine products include materials which are generally overseen by several categories of regulators and often through numerous FDA offices, complex administrative, technology and communication concerns emerge. Increasing component of the variation of regulatory pathways will impact regulation withall aspects of product manufacture and administration, include post testing, generic strategy, promotion, improvement and quality assurance, monitoring of harmful effects, advertising or advertising, and comment changes.[1]



Figure 1.1: Examples of drug-device, drug-biological, device-biologic combination products

1.2 World Market of Drug-device Combination Products-Coronavirus Effect (COVID-19) of a pandemic[2]

During forecast period, its global pharmaceutical combined products market increase is anticipated to also be slowed by the COVID-19 disease outbreak. The COVID-19 pandemic and the subsequent lockdowns in different countries across the globe have had an effect on the financial position of companies in all industries. The private healthcare sector was primarily affected by the COVID-19 pandemic. A number of clinical trials have been suspended during the pandemic. To resume clinical trials, the FDA published recommendations during the March 2020 public health emergency COVID-19. The Recommendations were further revised on 02 July 2020. Guidelines provide general considerations for supporting promoters and researchers to ensure the safety of trial subjects and compliance in this duration including its COVID-19 global health emergency, with Good Clinical Practice (GCP). The appendix to the Guidance also contains answers to certain general questions, FDA received from various sponsors and researchers about including execution of human research during in the global epidemic ofCOVID-19.

In 2020, the worldwide market of drug-device combination products is estimated at US$ 123.5 billion and has been projected to have a CAGR of 8.2 percent during the market growth (2020-2027).



Figure 1.2: Revenue Growth of International Drug-device Combination Products (percent) Study, Through Actual Product, 2020.

1.3 The concept of combination products is set out in 21 CFR 3.2. (e). This sameword organization and configuration

—A combination/hybrid product is an item that blends a biological product, a machine, and a drug in any form. The medicinal material in use in the drug mixture, including biological product system, is referred as a "component portion" including its combination product.

Those followings are used in a combined product

- **Single-entity** Items of variations. These products consist of two or more elements, i.e. drug/device, biological/device, pharmaceutical/biological, which are combined or blended mechanically, chemically or otherwise and are assembled as a single unit. Prefilled syringes, transdermal pads, or drug-eluting stents are examples of "single- entity" hybrid products.
- **Co-packaged** item of variations. Two or three separate products, available in a single application perhaps as a component, consisting of pharmaceutical and deviceproducts, biological and medicinal components or pharmaceutical and biopharmaceutical components, are included in similar pieces.
- **Cross-labeled** Item of variations. Such items are independently packaged medications, devices or biological products which are intended for use with only a licensed, specifically identified medication, tool or biological material in compliance with investigative policy or recommended packaging. To achieve the intended use, sign, or consequence, are both necessary. The labeling of the approved substance would need to be updated following approval of the proposed product, e.g. to indicate a change in planned usage, type of dosage, intensity, route of administration, or substantial dose change.
- **Injectable drugs, devices and biological materials that are individually prepared** as per the labeling, is to be used only with yet another investigational drug, device, or biological product which has been individually specified. To achieve its intended use, sign, or consequence, are both necessary.

Combination Product Types[3]

To describe the 9 various categories of a drug combination, the table below was generated. A package which includes only devices is not really a product of a combination. In addition, an item that is a drug-only combined effect is not really a combination product. If you've a substance does not appear to conform either of the Standard examples if you have concerns about

combination product categories related to Forms 1571 and 365h, notify the Product Authority Officer(s) of your Center for assistance. Contact the Office of Combination Products besides general queries concerningcombination product types.

Table 1: Examples of combination product.

Type	Description	Common Examples
1.	Co-Package for Functionality Under the same kit, medications and instruments are given as separate component pieces.	Vials of pharmaceutical products or biological products filled with equipment or accessory kits (empty syringes, auto-injectors, switch sets), first aid or medical kits containing devices and medicinal products
2	Device/ Device for Pre - filled Drug Delivery. The medication is loaded into or otherwise mixed with the system AND the phone's primary, aim would be to supply the drug	Prefilled opioid syringe, auto-injectors, fixedline dosage inhalers, nasal spray, dried powder nasal sprays, generators, transdermal devices, prefilled device or contact needle
3	Device/System Prefilled Biologic Transmission As well as the main aim of a device is to distribute the biological vaccine	Vaccine or other biological product in a pre - filled needle, auto injector, saline solution, injectable devices or micro needle patch refillable cartridges with both the biological product AND the biological item is filled through or otherwise mixed with device AND
4	Coated/ Inseminated Drug- Combined System An addition to consuming a medication, the system does have an extra feature.	Sensor-embedded drug capsules, drug-coated contact lens, cannabis stents, drug-eluting leads, spermicidal condoms, fluoride toothbrush, antibacterial coating bacterial tooth reinforces,
5	Encased and otherwise mixed system of Biologic. I order for distributing the product	Live cells seeded on or even in a device scaffold, that system has an additional function: extracorporeal column of column-bound protein
6	Integration of Drug/Biologic	In order to facilitate laser guided, immune response conjugated verbs, progenitor cells paired with such a medicine
7	Needing different goods	Label Marking Never co-packaged nor labeled for use with a particular transmitted light unit for light-activated medications or biological

8	Probable mix based on independent commodity cross-labeling	That drug/biological products during production uses another scanner, although it is unknown if the finished product needs these devices to have been cross-labeled.
9	Other Form of Part 3 Mixed Product (e.g. Medical Product/device/biological product)	Both 3 items are mixed with a single application (e.g. a pre-filled syringe the antibody-drug conjugate), a biomedical device which contains a drug/biological product in the box, one or two separate types of hybrid drugs.

1.5 The History of Combination Products[4]

As in 1970s, radiation biologics and in preclinical models were established that included the first combination drugs that fall under the FDA regulatory body. And for past two decades, every authority regulated combined substances on such an individualized level of including use of interdepartmental negotiations. And now the Safe Medical Devices Acts (SMDA), which contained a clause for the enforcement of such integrated products, was adopted in the 1990s. Which FDA has also elected to provide original responsibility. However it is also important to remember also that 21 CFR Section 3 (underneath) has been adopted but since the drug authority law was passed to 1991. This legislation ultimately came under its through 1997, the FDA Modernization Act (FDMA) was eventually enacted. Which Before the was considered by that of the FDMA clearance, warning, marking, marking, monitoring, inspection and registration of establishments, to name a few of the focus areas.

Even though mandated through SEC 204 including its 2002 Medical Device User Fee and Modernization Act (MDUFMA) was developed also by Office of Combination Products (OCP) through 2002



Fig 1.3 History of combination products pathways.

Through 2002, for more than 2 centuries, a FDA was also engaged to seeking to regulate, systematically and extensively, products which were not mere methods, and which were not just drugs, and real variations. A Offices of Combination Products (OCP) was foundedfrom 2002. For to both OCP's conception and thus the OCP's implementation, they wouldhave an application published in 2013 for just a CGMP for Mixture Products as well as a Permanent Regulation to 2004. Through 21 CFR Part 4, combination goods will have their own latest Good Industrial Practice Guidelines.

1.6 Role in the offices of Combination Product (OCP)[5]

A Combined Products Office was established on December 24, 2002, as prescribed by Section 204 including its Medical Device User Fee and Modernization Act of 2002. Which responsibilities are outlined throughout Provision 503(g) of the Federal Medical, Drug, and Cosmetic Act (21 USC 353(g)).

The Office of Combination Products (OCP) has the following responsibilities

- An act as a focus point for the combination product concerns and the recognition and assignment of medicinal items for the employees of the Department and the industry.
- Establish guidelines and legislation to explain the enforcement of combination goods.
- To identify prescription products as medicines, instruments, biological products or hybrid products or to delegate these to a FDA Pre-Market Assessment and Regulatory Centre.
- Ensure prompt and successful pre-market analysis of combination goods through tracking Reliability, consistency of assessment scheduling involving upwards of one authority hub, involving supervision and control of that same based on cross enhance the professional
- Maintain dependable and the reasonable for post-market control of combination goods.
- To settle disagreements surrounding the timeliness of the pre-market analysis of combination goods.

1.7 Main Operation (PMOA) with Combination Product-USFDA[6]

In deciding the regulatory approach for combination product applications, including that of the FDA curriculum, PMOA has been the most important factor.

PMOA has been the single mode of action of a combination substance, when described by 21

CFR 3.2(m), which offers most meaningful therapeutic action. An main centre onlyat FDA is allocated by this description, and while one might assume it'd be the Office of Combination Products (OCP), it is not. Depending mostly on PMOA, many of the 3 center will have be allocated

- Center for Drug Evaluation and Research (CDER)
- Center for Devices and Radiological Health (CDRH)
- Center for Biologics Evaluation and Research (CBER)

Examples of combination product: Drug-eluting stents (DES) are checked for certified by FDA's Center for Devices and Radiological Health (CDRH), also known as FDA's device arm, under 21 CFR 3.2(e) – a mixture of either a drug and perhaps a device in just this circumstance.

Responses for drug-eluting stents (DES) generally consist of pre-market approval (PMA),

1.7.1 Agency Assignment

Is this obviously a pathway for device submission, A medical equipment product code (NIU) is allocated to the product and the testers are from the Office of Device Evaluation (ODE). In a summary, a drug-eluting stent is regarded also as surgical appliance.

Assessing your PMOA helps each agency could devise their regulatory policy.

- PMOA = device --> lead agency = CDRH
- PMOA = drug --> lead agency = CDER
- PMOA = biologic --> lead agency = CBER

Those certain constituency notification pieces are typically outsourced to certain other departments through analysis, yet this lead was compensated for terms of purchasing.

Illustration: Commitment of PMOA

- Combination products : Expected Consumption to Be used: Epipen Auto-Injector
- Intended use/ indication for use: EpiPen and EpiPen Jr Auto-Injectors are all about the emergency treatment of existence adverse reactions (anaphylactic) triggered by toxins, activity, or unexplained stimulates; and for individuals who may be at elevated risk for all these incidents
- MOA Assessment

a) Instrument (Injection system Pen): holds the medication (container) and assists in accessing the patient's body (needle).

b) Antihistamine (Epinephrine): Epinephrine is an antihistamine that really can greatly reduce, interrupt, and avoid anaphylactic shock accompanied by toxins, movement, or other causes.

c) PMOA Estimation: That drug Epinephrine was its PMOA throughout this situation regardless. it provides the most critical therapeutic action that addresses the indications. Furthermore, by reviewing the FDA Guidance Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products, it can be determined that most pen injectors used with drugs are classified as ―Drugs‖ where the main submission pathway is a New Drug Application (NDA) – or a derivative such as a 505(b)(d) – and the lead agency is CDER.

Table 1.2: Comparison of regulatory aspects of Drug and Devices and biological.

	Drugs	Devices	Biological
Regulated by	CDER	CDRH	CBER
Relevant section	Drug CGMPs (12CFR part 210-211)	Devices CGMPs (21CFR part 820)	Biologics CGMPs (21CFR part 600 -680)
Emphasis	Quality system • Corrective action and preventive action • Individual outputs Large Clinical trail Risk assessment (but not really)..	• Quality system • Design control • Quality by design • Risk assessment • Process as a continuum • Small, focused clinical trial maybe	• Candidate records • Manufacturer data • Pre-clinical research • Medical trials • Marking
Timeframes	Long (6 -10years)	Short (1 – 5years)	Long (8 -9years)

Table 1.3: Combination products applications per the PMOA including evaluationtime.

Lead center	Application type	Review clock
CBER/CDER Lead	NDA or BLA	6months (priority review) or 10months (standard review)
CDRH	Premarket Approval	180days
	Premarket notification 510k	90days
	HDE- Humanitarian device exemption	75days

1.8 JURISDICTIONAL OF COMBINATION PRODUCTS

1.8.1 Pre-Request for Designation (Pre – RFD)[7]

The method of Pre-Request for designation Specifically, at the Office of Combination Products

(OCP), this guide outlines the Pre-RFD process and helps a supporter recognize the source of data to be given in a Pre-RFD.

Aim of providing confidential, semi information concerning its regulatory identification ordesignation of the product as a drug, device, biological products of pre-RFD is available.

A Pre-RFD is a straightforward and descriptive documented application that could be made by a participant to the OCP to demand the provisional, non-binding evaluation of the FDA.

- The regulatory classification of a product as a pharmaceutical drug, and device, biological or combined product.
- When the product will be governed by CBER, CDER or CDRH that either of thoseAuthority Center can have primary authority, if it is a combination product, for pre-market inspection and regulation.

Information should i include in a PRE-RFD

1. Company contact along with the title, company's title, email, and contact number.
2. A fully recognizes of a product, and the proceeding data, if relevant. 510(k), Premarket Approval (PMA), (NDA), (ANDA), (BLA), and any other product- related Regulatory authorities submittal number, New product and then all elementproduct lines; brand portrait.
3. Describe the how content was treated and the description of the identification of the finished product for that from biologically derived materials.
4. An description of how the object functions. And, although optional, you may provide supplementary material explaining details of specific data that demonstrates how the product works
5. The product has individually sold component elements to be branded together through use, or may have elements which will be integrated either chemically or physically to form a single entity or will be co-packaged.
6. The product has operating segments sold separately to be branded together by use, and may have components that may be combined or co-packaged either physical or chemical to form a single entity.
7. Draft declaration of use/intended use/indications for use.

8. Usage instructions/conditions of use.
9. Both recognized intervention strategies as well as the factor(s) for which both are done.
10. Some details that you would provide in favor of a comparative presence of different ingredients, if any, of the overall intentional beneficial effects of the drugformulation, with products that might be mixed drugs.
11. A collection of statements you intend to implement and have made with respect to the object.

1.8.2 Request For Designation: The RFD is often alluded to it as a document of inquiry by a claimant (see 21 CFR 3.2(j)). It is a registered OCP request. Generally, RFDs demanda declaration of

Document we intend to be used in an RFD[8]

You must have the start to finish within your RFD, as appropriate, however according 21CFR 3.7(c).

1. Its promoter's contact details, as well as the manufacturer's entity physical address, contact information, and email address.
2. The standard description, which include

- Category description, brand, and all constituent products, whenever appropriate;
- Company standard, generic, or normal title, so all individual product lines;
- Commodity patented address;
- Detection about any component of a substance that has since obtained or before regulation, is introduced to the market as for not needing which was before consent, or has required a legislative exception, the sponsors' names, and the existence of any contracts or arrangements with the sponsors about the inclusion ofthat product as part of its new operational and strategic levels;
- Chemical, functional, or molecular concentration;
- Improvement including comprehensive documentation of the results of infrastructure developments, including testing on animals;
- Description of framework, including all the nature of most all inputs;
- Analysis of all known pathways, as well as the promotional description of the particular safety profile that defines the product's most attractive biological action and the essential controlled release.

- Procedure and time usability;
- Dose and route of exposure of drug or biology;
- Description of comparable products, such as that of the importance of all of thesematerials in legislative execution.
- All the other applicable detail.

3. Whether the Authority part may have considerable consequences, according to the promotional recommend.

REVIEW OF LITERATURE

1. **Specialized Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted under a BLA, NDA, or ANDA (2020)** This rule incorporates injectors for dire utilize gave under a Biologics License Application (BLA), New Drug Application (NDA), or shortened New Drug Application (ANDA). The word 'pressing injector' demonstrates an infusion framework sold as a pre-filled single individual blend gadget under 21 CFR 3.2(e)(1) or a co-bundled mix item under 21 CFR 3.2(e)(e) after a critical medication 21 CFR 3.2(e)(2). The earnest injector contains pen injectors, auto- injectors or on-body conveyance frameworks for pressing consideration prescriptions other than conditions including such hypersensitivity, excess of narcotics, tainting, or extreme high glucose.

2. **Requesting FDA Feedback on Combination Products (2020)** Those very encounters may take place via the framework processes, including the pre-submission procedure usedfor the Center for Devices and Radiological Health (CDRH) as well as the Center for Biologics Evaluation and Research (CBER) as well as the regular presentations used during the Centers for Drug Evaluation and Research (CDER) and CBER, or, where necessary, through the Combination Product Agreement Meetings (CPAMs). Paragraph 503 (g) (8) (C) (vi) necessitates this same FDA to release a solution and the concentration discussing: (1) the organized plan for identifying pre-submission encounters to endorsements that evolve combination products; (2) best practices for ensuring that FDA input in those kind of pre-submission encounters is the Agency's biggest compliment facts provided during all those pre-submission relationships. (3) that CPAMs pertain to many other kinds of FDA meetings, what information should be given with such a CPAM query, as well as the establish and

material of a CPAM contracts.

3. **Principles of Premarket Pathways for Combination Products (2019)** Section 3038 of the 21st Century Cures Act, enacted in December 2016 (P.L. 114-255) (―Cures Act‖), substantially revised area 503(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act)(21 USC 353(g)), the chief segment of the FD&C Act explicitly tending to mix items. A thematic elements of such provisions entail strengthening the clarification, consistency, effectiveness and accuracy of pre-market addressing identified for mixed products, as well as by guaranteeing that its pre-market evaluation of these products is properly coordinatedby components and personnel of a Agency but that the thoughts of the Agency is associated in the behavior of those evaluations. Is part of its plan to implement Sections 3038 of a Cures Act and in line with both the lengthy dedication of a Department to accountability, quality, and procedural compliance, the FDA is releasing these guideline to promote the production of healthy but efficient combination drugs.

4. **Bridging for Drug-Device and Biologic-Device Combination Products (2019)** Although pharmaceuticals, instruments even biological products maintain a distinct regulatory classification because they are components of either a inevitably result, coagulated form a different group of medicinal products which may be prone to specific regulatory criteria. That constitutional obligations relating for combination products thus derive from the laws and regulations relating to drugs, instruments and biological products. That FDA are dedicated to implementing a clear, danger strategy that resolve related regulatory concerns, even science problems, throughout compliance with section503(g) of a Federal Food, Drug, including Cosmetic Act.

5. **Post marketing Safety Reporting for Combination Products (2019)** For combination goods which have earned FDA marketing permission, the regulation specifies how and when to conform with PMSR criteria. While there are certain parallels between the PMSR regulation for medications, equipment, and biological products, each set of laws defines different testing standards, including notification mechanisms and timelines. It order to obtain proper and full documentation thus preventing overlap, its proposed rule outlines the extension of such administrative standards to combination goods. Basic info on drug

substances, the how FDA governs hybrid goods as well as a description of a PMSR drug combination proposed rule are given in Section II including its Guidelines. Section III offers a description of which organizations are subjected to the draft report and of the criteria applicable to those organizations for residential stability. Very full review of unique combination product PMSR report forms is given in Section IV. Section V includes guidelines about where to send PMSR files to the FDA, why, and when. Section VI proposes imaginary conditions that demonstrate comply with certain combination product PMSR requirements

6. **Pre-Request for Designation (Pre-RFD) (2018**) His guide is designed to help investors achieve a qualitative review from of the U.S. Administration of Food and Drugs (FDA or Agency) by the method of Pre-Request for Designation (Pre-RFD). Accurately, at just the Office of Combination Products (OCP), the whole protection system the Pre- RFD system and results promoter recognize the sort of communication to be provided in a Pre-RFD. Besides unofficial, semi information regarding the governmental individuality or classification of a human pharmaceutical drug both as drug, device, biological product but rather coverage and high, this same Pre-RFD system is performed.

7. **Current Good Manufacturing Practice Requirements for Combination Products (2017)** Section guideline outlines and discusses the final regulation, released by a FDA on January 22, 2013, regarding CGMP specifications for combination products (initial rule as codified in 21 CFR section 4). While CGMP regulation were all in force to set specifications for medicines, instruments, biological products, and cell cultures, tissues andcellular or tissue-based product lines (HCT/Ps), prior to issuance of both the draft report, In order to illustrate and justify the implementation of these CGMP specifications to hybrid goods, there were no rules. The final rule was designed to include such guidance and to clarify how conformity can be illustrated with the relevant CGMP specifications.

8. **Glass Syringes for Delivering Drug and Biological Products (2013)** A key component of acute management is bottle needles promised to produce drugs or biologics to a clinician. Glass syringe also actually knowing besides linkage to many other devices, like infusion beads, intravenous line (IV) connections, needleless luer locks, connectors, and transition

bases. In November 2010 and May 2011, the Government approved Stockholder or Security Notifications instructing on adverse events and quality control issues pertaining to connectivity issues if some needleless IV visualization are being used with other prefilled central venous glass syringes. Such occurrences will result in a delay in medication administration throughout emergency cases and might possibly cause significant injury to patients.

9. **Entries for Post endorsement Modifications to a Combination Product Approved Under a BLA, NDA, or PMA (2013)** The successful way has been apportioned to either a middle (CBER, CDER, or CDRH) with essential ward (the lead place) for premarket audit but instead post-market guideline, under Paragraph 503(g)(1) of each Federal Food, Drug, just as Cosmetic Act (FD&C Act). A task of a lead community has been taken as a proportion of the blend item's essential method of activity (PMOA) and other straightforward lawful rules, given additionally that PMOA could be characterized with complete precision. In specific cases, the FDA could limit the entire mixed item into one segment of advertising application assessment, task (e.g., one BLA, NDA, or PMA). It solicitation ought to give all the subtleties needed to legitimize the acknowledgment including its controlled substance itself, with all the segments of item (medicine, framework as well as natural material.

10. **Request for Designation (RFD) (2011)** Specify the category of details suggested by the Office of Combined Items (OCP) and include a source in a Submission for Classification (RFD). He purpose of such a guideline is to enable a promoter identify the process of details needed by the FDA to establish a device's product identification or classification as a drug, system, biological product or hybrid product and also to allocate the product to a company or analysis and enforcement, an effective Organizationalpart.21 CFR Section 3, as modified by Final Rules mostly on definition of a primary mode of action of a combination substance (PMOA). The policy archives of the FDA, except for this regulation, may not define constitutionally implementable commitments. Typically, guidelines view the current thought of the Organization on even a subject that could only be considered with guidelines until clear legislative or legislative criteria be listed. Within Organization guidelines, use of the word indicates that this is proposed and advised, but itnot needed.

11. **Early Development Considerations for Innovative Combination Products (2006)** The FDA acknowledges that even a variety of science or technological advancement concerns can emerge from emerging technologies. Progressively, combination goods integrate having to cut, novel innovations that carry great promise to advance healthcare services. Besides example, by helping prevent vasoconstriction which might occur upon stent implantation, drug-eluting cardiovascular stents could decrease the need for repetitive surgery. In order to eventually protect the security and/or efficacy from either item pure active, drugs and biological products could be used in combination.

12. **Application User Fees for Combination Products (2005)** A supervision article outlines that perhaps the client fee related to a specific form of marketing application must be evaluated for the mixed products under which a marketing communications proposal is published. This same report illustrates that three service fees will also normally be reviewed in such a strange event at which FDA uses two identifying the features for just adrug combination. Which guideline further explains that how "bridge for creativity" exemption clause can be extended to innovative combination products for which the FDA needs the introduction of two proposals under the prescription medication patient charge requirements of every Federal Food, Drug, and Cosmetic Act (the Act). A decrease in application user costs equal to both the increased cost higher resistance with submission of two advertisement applications will allow for this exemption.

AIM AND OBJECTIVES

3.1 AIM

The aim of the study is pre-market, post-market, and clinical trials guidance documents of the regulatoy requirements for the combination products as per USFDA guidelines.

3.2 Specific scopes are

- To study the combination products for pre-market regulations as per USFDA guidelines.
- To enumerate the regulatory dossier requirements of post-market regulation of combination products as per USFDA guidelines.
- To study the post- approval submission for modification to a combination products approved under the BLA, NDA or PMD

- To study the Current Good Manufacturing Practice including combined production schedule.
- To study the combination products of e CTD requirements (dossier)
- To elaborate the clinical trial guidance documents of combination products
- To study the regulatory challenges and submission of combination products.

RESEARCH METHODOLOGY

4.1 METHODOLOGY

The method begins with the scope and objective of the premarketing, post- marketing and clinical trials documents in the combination products of requirement in USFDA guidelines. According information collected by the regulatory bodies, their recommendations and the view of experts. The findings of the whole analysis were collected, and the results were discussed before a decision was reached. Research methodology is a way to systematically achieve the study objective. In this chapter a brief description of the following is provided

- Study types
- Sources of data
- Internet using the web page content.

4.1.1 Study types

- A study conducted done with the aim of trying to set out another regulatory requirements of its pre-market, post-market, and clinical trial guidance, regulatory challenges and submission of the combination products as per USFDA guidelines.
- The study of the premarket and post market regulatory requirements of combination products. and enumerate the regulatory dossier submission of the products.
- To study and elaborate the clinical trial guidance document of the drug- biological, medical device, manufacturing requirements of investigational products, and investigational review board and informed consent of the information described as per USFDA guidelines of combination products
- To evaluate the combination products dossier submission and regulatory challenges begins that the outcome of the exclusive analysis on the subject in orderto speed up the results. The needs to organize were used to obtain a considerable volume of quantitative information.

4.1.2 Sources of data

In this comparative study mainly secondary sources of data have beenreferred to which include the following

a) **Literature review:** Scholastic diaries, Online diaries, statistical surveying reports, paper articles, and different assets, and direct correspondence with administrative specialists. Online books additionally filled in as a decentwellspring of data.
b) **Websites of different administrative offices and association:** Normally covered the administrative rules distributed formally by offices andsites identified with the enlistment prerequisites for administrative bodies
c) **Guidelines and guidance document issued by the regulatory authority of theUSFDA included in the study:** Rules should give the most helpful data and the data referenced in the rules was standard, everybody attempts to follow these rules.

4.1.3 Internet using the web page content. Various regulatory website have been used to obtain information for this thesis.

https://www.ich.org/ https://www.access.fda.gov/
https://www.federalregister.gov/agencies/food-and-drug-administration https://www.fda.gov/home
https://www.fda.gov/combination-products
https://www.fda.gov/regulatory-information/search-fda-guidance documents/combination-products-guidance-documents
https://www.who.int/publications/who-guidelines
https://sci-hub.se/
http://www.ijdra.com/index.php/journal

RESULTS AND DISCUSSION

5.1 COMBINATION PRODUCTS OF GUIDANCE DOCUMENT

Combination products guidance document of the premarket, post-market, clinical trial documents of the regulatory guideline documents listed in study and discussion part. In this section, guidelines are listed in each section of the industry guidance documents.

The table beneath records all authority FDA Guidance Documents and other administrative directions.

5.1.1 PREMARKET - COMBINATION PRODUCTS
Submission and Resolution of Formal Disputes Regarding the Timeliness of Premarket Review of a Combination Product
Early Development Considerations for Innovative Combination Products
Application User Fees for Combination Products
Glass Syringes for Delivering Drug and Biological Products: Technical Information to Supplement International Organization for Standardization (ISO) Standard 11040-4
Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products
Human Factors Studies and Related Clinical Study Considerations in Combination Product Design and Development
Principles of Premarket Pathways for Combination Products
Bridging for Drug-Device and Biologic-Device Combination Products
Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted under a BLA, NDA or ANDA
Requesting Food and Drug Administration Feedback on Combination Products
5.1.2 POST MARKET - COMBINATION PRODUCTS
Submissions for Post approval Modifications to a Combination Product Approved Under a BLA, NDA, or PMA
Current Good Manufacturing Practice Requirements for Combination Products
Post marketing Safety Reporting for Combination Products
5.1.3 COMBINATION PRODUCTS OF ECTD REQUIREMENTS (DOSSIER)
General arrangement remarks
Module 1, Section 1.2
Module 1.1. Structures
Module 3
Module 5
5.1.4 CLINICAL TRIAL GUIDANCE DOCUMENT
General information sheet
Drug- Biological information sheet
Medical device information sheet
Investigational review of boards and informed consent sheet
Manufacturing requirements of investigational products

5.2 REGULATORY CHALLENGES AND SUBMISSION OF COMBINATION PRODUCTS

The regulatory challenges of combination products although many of the problems relatedto the development and distribution of combination drugs still relate to individual treatments, the possible complications can be exacerbated due to the highly dynamic design of these products in drug-device, biologic-device of the challenges in a regulatory submission.

Current regulations, challenges and global trends
Challenges of combination products
Practical challenges and opportunities

5.1.1 PREMARKET -COMBINATION PRODUCTS

5.1.1.1 Accommodation and goal of the conventional debates in regards to the idealness of the premarket survey of a mix Product

Presenting a proper question in regards to the dependability of the investigation of a blended item pre-market application. This demonstration made the Commission of Mixed Goods inside the Office of the Commissioner for Food and Drugs (OCP). Creation and execution of approaches and methodology for the smoothing out of medication gadget, drug-organic and gadget natural mix exploration and controls.

Applicable time frames

For certain types of pre-market implementations of drugs, equipment, and biological goods, the Prescription Drug Consumer Fee Act (PDUFA) and MDUFMA set output goals. In disputes relating to hybrid customer reviews, OCP intends to interpret the data sets foundin PDUFA and MDUFMA performance goals in the following manner:

- When a hybrid commodity is to be evaluated under one and two pre-market demands, OCP tends to take into consideration the time frames associated with thatkind of pre- market application.
- OCP plans to accept time limits applicable to hybrid goods even though the customer does not incur a user charge.

Interaction for introducing an idealness debate goal solicitation to OCP The OCP exhorts that the inquirer first location the situation with the audit with the exploring division and additionally the Office to which CBER, CDRH, CDER, OCP, OCP, the evaluating segment reports inside the lead place.

OCP respond to a request for resolution of a timeliness dispute

1. Where the Section Manager and the Main Attorney agree that the relevant userfee time period has not been met;
2. The genuine state of the review;

3. Issues which need to be resolved until the analysis can be finalized;
4. The OCP will do so in order to promote the adoption of a positive outlook and, if appropriate and possible, of a timetable for the implementation of the evaluation, including the firm date for the conclusion of the research.

Data ought to be remembered for a practicality debate goal demand - An idealness contest goal solicitation ought to incorporate the accompanying data.

- Contact Information for the application structure;
- Name of the item and data with regards to whether it is a blended item;
- The number of the Submission for Approval if the item has experienced the Application for Designation measure;
- Pre-market investigation by the FDA Center and the examination office;
- Application number appointed by the Center or Division of Review;
- Form Application;
- Any important objective of creation for the utilization expense;
- The date of the petitioner's supposition that the claim was expected;
- Name and contact detail of the Patient Advocate for the FDA Application;
- A depiction of subtleties given by the assessing segment in the number one spot place on the dependability of the audit

5.1.1.2 Early development considerations for innovative combination products[9]

The development requirements for new technologies for industry and FDA combine resources, medicines additionally products of genetics. These are policy framework for previous meeting mostly on form of scientific and technical expertise that may be needed in applications for investigation or promotion of such combination items.

I. **General development consideration** Made by mixing production processes generally focuses on the science and technical issues posed by the specific item being made. The mixture product itself and its constituent elements of a combination product would usually reflect these scientific/technical issues.

II. Points of view by constitutive portion

A. Device constituent considerations

The scope of preclinical testing will focus largely on the current use of the device constituent as much of the combined product for elements of the device constituent that have already been authorized for the next purpose. It is therefore necessary to consider itspotential association (talked about wanting or undesired) here between mechanism as well as the drug/biological constituents.

Leachable of the device materials into the drug/biologic substance or final combination product;

- Variations in the drug constituent's consistency as supplied by the device.
- To components of the system that might affect the dosage delivered;
- Existence of active decay materials or processing contaminants from the productionof devices that may influence protection or system behavior that could modify the characteristic of drug output at the time of use;

B. Drug and biological product constituent considerations

If another portion of a combination product would be a novel molecular entity (NME), this was necessary to consider which information is required to explain its efficacy and safety of the NME included within the combination product. The following are descriptions about where further clinical trials or medical safety data or new drug testing might be needed for both the drug/biological portion.

- Drug or biological product accepted with shift in dosage, power, deliverymethod;
- Fresh dosage (e.g. total dose, length of dosing, schedule of dosing, or average exposure);
- Fresh demographic of patients (e.g., pediatric, geriatric, pregnant or nursingmothers, or change in condition of sickness or disease).

III. Additional perspectives

A. Clinical Investigation

For many mixed drugs, for both the preclinical studies of both the combination product itself, one investigational application (Investigational New Drug (IND) or Investigational System Exemption (IDE) application is requested.

B. Manufacturing considerations

During the production of a hybrid commodity, processing, size, and performance measurement are major factors. Methods and techniques for production impact either pre- market growth and post-market control.

When pre-clinical and clinical trials are conducted and during pre-market investigation, any possible improvement in the supply chain for the components of the drug, biological or system or combination product can influence the safety or efficacy of the combination product itself.

5.1.1.3 Application User Fees for Combination Products[10]

User Fees

- The hybrid product checked by the CDRH would typically be subject to device usage fees and probably other fees, such as registration fees.
- CBER for appraisal will be subject to the criteria for the prescription drug patient charge for the combination medication allocated to CDER.
- PDUFA facilities and costs for consumer replacement. Organizers may be eligible for fee exemptions or limited under PDUFA and MDUFMA.

Eligibility criteria for fee waiver

- The integrated commodity as a whole has been groundbreaking.
- The FDA requires two fee-eligible promotional demands for hybrid goods.
- The demands only ask that the key components of the hybrid package be approvedfor mixed use. In addition, there would be no eligibility for this exclusion for devices that use or even both modules outside the combination.

Table 5.1 Application user fees of combination products.

Single application/fees	Available waiver/reduction
NDA/PDUFA fees BLA/PDUFA fees	Waiver applicable to single PDUFA applications • Small business; • Barrier to innovation; • Essential for public health protection; • Fees would surpass the FDA's projected current and potential review expenses.
PMA, BLA, or 510(k)/MDUFMA fees	Waivers applicable to single MDUFMA applications

	• Small corporation Humanitarian device exemption BLA for a system only approved for potential development use • Third party 510(k) Any device program planned exclusively for pediatric use.

5.1.1.4 Glass Syringes for conveying Drug and Biological Products: Technical Recommendations to Supplement International Organization for Standardization (ISO) Standard 11040-4[11]

The FDA has approved Regulation 11040-4 of the International Organization for Standardization (ISO) for glass syringes used to distribute medicines or biological products. For glass syringes, the FDA have decided whether showing compliance with the ISO 11040-4 requirement alone does not guarantee can be correctly attached to the attaching equipment.

The rules found in this rule paper will allude to an ally of IDE, HDE, 510(k), or PMA as to the accompanying glass needle items and to the ally of an IND, BLA, NDA, or ANDA in regard of a therapeutic substance or an organic item provided with the relating glass needle item:

- Prefilled needleless glass needles with both a medication or even a natural item;
- Empty glass needles co-bundled with both prescription or an organic substance as well as framework for association,
- Empty glass needles intended to be utilized for meds or organic that have been publicized.

FDA Recommending

He FDA recommends which manufacturers submit documentation to confirm which their glass syringe has compatible (functionality) to attaching equipment in order to provide safe delivery of the drug or medicinal material. An order to achieve this, details well beyond the documentation given for conform with ISO 11040-4 should be used or used in the crystal needle layout. Under subparagraph A, The proposed design or re-design decisions are mentioned. The general data formats and information recommended by the Departmentin the pre-market or investigative submission for glass syringes are described in subsection.

Recommended design or re-design options

- Choose a secured or tapped arrow for subcutaneously injections with a suitablesharp safety feature.
- Plan the internal dimensions of the glass needle that guarantees accessibility to connecting devices.
- Create designs the glass needle and the linking equipment for specific dual connections.

Information and details suggested by the Department to be used in pre-market applications

i. Data and details showing conformity with applicable ISO requirements recognizedby the FDA to ensure connecting interface compatibility:
ii. Syringe's Practical Performance:
iii. Biocompatibility: Evidence and information showing ISO 10993 congruity with an assortment of, where relevant, physicochemical, insightful and natural exploration.
iv. Sterilization: Evidence and subtleties showing consistence with the FDA's rule paper, "Accommodation Documentation for Validation of Sterilization Process in Human and Veterinary Drug Product Applications," as pertinent.
v. Human Factors - Evidence and information from research of human factors

5.1.1.5 Technical Considerations for Pen, Jet, and Related Injectors for use with Drugs and Biological Products[12]

Scientific and Technical Considerations for your premarket submission

A. Injector Description: Expanded the degree of injector plans, they recommend that maybe an itemized outline of your gadget, its indication(s) being used, and its terms of the utilization be remembered for your pre-market accommodation. The accommodation may contain, contingent upon the thing, the accompanying things, as material:

1. Identification

- Market penetration or even the injector's exclusive name
- Compatible designation; e.g. the injector's generic or many other identity
- Control on system designation (e.g., 21 CFR 880.5860) and product code (e.g., NSC).

2. Usage Confirmation

- Statistical user (e.g., medical disorder, demographics)
- Location of injecting (your area in which the individual is filled with the medication material)
- Intentional infusing layer and time of infusing (e.g., subcutaneous, intramuscular, intradermal)
- Category (e.g., singular patient use as a solitary, dispensable, reusable, or refillable injector)
- Intention yet utilization of things (e.g., for general use or for use with an item class, family, product offering)
- Expected client (e.g., patient, parental figure, medical services supplier)

3. Description of Conditions of Use

- Package design (e.g. as just a well before fuel injection system product, as just a founder comprising the fuel injection system or assembly medication item)
- World of conditions of use (e.g. house, education, battlefield),
- Packaging, treatment and some other use considerations for post injectors, e.g. airflow, atmospheric and/or light protection conditions, or room temp pre- injector acceleration heating.
- Type of infusions (e.g., manual cylinder, spring load, gas, fly, other)
- Medication item or administrations) for both the conveyance of the infusion framework
- histogram Specification of excesses (e.g., single-portion, numerous portion, movable portion)

4. Portrayal of Drug/Biological Product for Injection

3 independent user classes for injection system as available

- Valves intended for use on a wide scope of legitimately promoted drugs/organic items; (general use);
- Valves intended for use with a specific class or post photos of legitimately promoted drugs/organic items;
- Valves proposed for use with a particular medication/organic substance as it were.

B. Design Features The design aspects include the injector's technological requirements, the characteristics of a injectable device, the arrangement of the injector (e.g. general usage, pre-

filled or co packaged and the human factors to be addressed in order to guarantee the product's secure and efficient use. Where a general usage device under 510(k) is submitted.

1. **Comparison to an Existing Delivery Method** Manufacturing companies can compare different features of their injection system to features in comparable legally packaged goods to encourage the regulatory examination of the injector. Depending on the use of the injector and the regulatory pathway for the injector, the purpose of this comparison varies.

a) **Particular utilization injection system (510(k) activation):** The 510(k) sales process constitutes action with substantive equivocation to a sold legally injection system preposition (s). 18 Examples of comparable knowledge that you can include in an application of 510(k) are the following. See also Section I.D., Performance Testing, for additional detail.

- 510(k) number(s) of the predicate(s)
- Guidelines for using the latest injector
- Terms of use
- Treatment facilities
- When relevant, injection path needle penetration depth
- Injection system life
- Suitable tubes
- Where relevant, integrated cartridges
- Dosage, dosage accuracy, inject pace, infusion intensity andreliability.
- Overall dimensions of power supply
- Weight Design characteristics
- Construction materials
- Performance requirements and specification (e.g. power, pressure)
- Where necessary, projectile lumen and jet fuel pump nozzleappendage scale
- Drug/biological product(s) planned to be used with the injector

b) **Prefilled injectors,** Injectors co-bundled the with drug/biologic or autonomously sold yet marked injectors and medication/biologic there under NDA/BLA pathway.

2. Portion Setting and Administering an Injection

A specific for all the FDA to decide the attainability of the infusion framework to create the required bring about high of the objective medication/organic product(s) into the helpful specialist in a steady and reproducible way just as to liken the unwavering quality and reproducibility with that of the up-and-comer injector (or another conveyance strategy as suitable), We suggest that you incorporate an outline of the medication/natural measurement climate and organization conventions while utilizing the most recent and predicated injector, including (if appropriate):

Collecting the injector at the purpose of clinical use

- Loading the medication/natural item
- Priming the injector
- Pre-setting the portion
- Inspecting the medication/natural item
- Preparing and situating for an infusion Adjusting the portion
- Resetting after use
- Changing and discarding the needle

3. **Graduation Marks and Fill Lines** In assist the organization in determining the optimum dosage or even to check the defined dose, qualification markers and filling outlines could be used. In order to assist appropriate daily doses in compliance with the licensed drug/biological product labeling, we request that all these marks be used in the layout of the injector, when:

- Several doses of a drug/biological substance are supplied by the injector;
- The dose may be changed by the patient; or
- The injector is designed to include a single dosage of a given drug/biological substance and, as defined by a risk study, the risks associated with mis- or over- dosing are important.

4. **Medication Product Enhances Work** This same drug/biological distribution function features labeling directions which include a spot inspection of the product tubes containing, even in circumstances.

5. Safety Features

To achieve correct dosing and avoid sharp damage, injectors can have a range of safety features. These functions can include auditory, visual, even tactile alerts and also some switches including mechanical safeguards, in comparison to graduation/fill points and visual inspection.

6. Human Factors Design Considerations

The planned consumer population, anticipated signals for usage, as well as the atmosphere for use can be taken into account in the injector design.

C. Inlet valve Construction and Manufacturing Products Required

Components which included the injection system are alluded to as the assembly widely used in the production of an injection system as your advertisement thinking to separate. Examination of leachable emerging from the connection between the medication/natural item and injector.

- Review of recoverable impurities from the injector sections under research centre circumstances and availability of extract profile
- Review of medication/organic products (going to count additives) adsorbents onthe part of the injector
- Study of volatile face mixtures where the compressor is the main regulatory inference for both the medication/biologic
- Study of long-term partnership of drug injectors with re-useable valves
- Examination of a degradation of practical resources from interaction to medication/biological products.
- Analyzing the integrity of seals
- Identity and analysis of the effects of presence.

D. Product Specification: Injection system Requirements of Specific Consumption

With common usage, implementation checking Valves may be with the last injection system as view and therefore should accept the characteristics of the wide range of medicines goods in their last supported medicating system (taking into account the confirmed implantation dilution series) in which the electric motor is scheduled to be used.

- ISO 7886-1: Sterile Hypodermic Syringes for Single Use - Part 1: Syringes for Manual

Use

- ISO 10993-1:Biological Evaluation of Medical Devices - Part 1: Evaluation and Testing
- ISO 11608-1:, Pen-Injectors for Medical Use – Part 1: Pen-injectors – Requirements and test techniques
- ISO 11608-2: Pen-Injectors for Medical Use – Part 2: Needles – Requirements and test techniques
- ISO 11608-3: Pen-Injectors for Medical Use – Part 3: Finished Cartridge – Requirements and test techniques
- ISO 11608-4: Pen-Injectors for Medical Use – Part 4: Requirements and testtechniques for electronic and electromechanical pen-injectors
- ISO 21649: Needle-Free Injectors for Medical Use - Requirements and TestMethods.
- ASTM D4169:, Standard Practice for Performance Testing of Shipping Containers and Systems

E. Efficiency Checking: Characteristics of injectors and medication products For a ratherwide used valve, your accuracy test results for either the final tube and for final end pharmaceutical formulations for assessing the reliability of the overdose of the drug/biological substance as well as for the degree and route of the injections is included in the application in compliance with the guidelines specified in section ID.

1. **Dose Accuracy** The accompanying infusion portion consistency checks for the medication/natural substance in its affirmed dose structure for infusion, and utilization of the endorsed diluent if important, was recommended by the FDA using the last injector.

2. **Range and Application Routes** Checking can show that drug/biological substance also in target tissue is correct and compliant with the depths of particle passage and/or absorption.

3. **Special Testing Considerations** If another container closing device for the chapter provided product is not included with injector supplies, then you can take the necessary actions in vitro assay to verify the efficiency of your injector for the chapter provided product.

F. Performance Testing: Medical Concerns The purpose of this guideline is beyond practical considerations for the nature of clinical trials. Research on social factors will determine

consumer experiences with both the injector or whether the targeted consumer group will use the injector for the specified drug/biological substance safely and efficiently.

G. Vaccination and Protection of Toxicity

1. **Vaccination Control** Vaccination entails two components: the antibiotic resistance protection needed in both the injection system itself as well as the sterilization promise up with the final finished inlet valve product overall.

2. **Cross-Contamination Potential** A large proportion of injection system for individual health use would be licensed or cleared. Multi-patient injectors, Typically pose serious questions regarding the possibility of transfer through patient to patient of blood-born pathogen or skin contaminant.

5.1.1.6 Human Factors Studies and Related Clinical Study Considerations in Combination Product Design and Development

The essential ideas of human components (HF) research, as portrayed in 21 CFR Part 3, during the creation of mixed merchandise. This rule clarifies Department rules in a half and half item request or mission application on HF subtleties and explains the different types of HF considers

Human Factors

A. Glossary and Concepts

1. Human Factors Study (or HF Study): A analysis was performed with sample consumers to determine the appropriateness of the architecture of the combination device interface to remove or minimize potential hazards associated with use. The HF research assesses.

B. Multi - purpose Risk Analysis Using of risk analysis of the a hybrid item should become the basis of HF research designs, assessment tools, aligned with a threat manufacturing and building model.

C. Human Factors Formative Studies HF Instructional tests are based samples of late combination items, keeping in mind using of hazards found. In order to remove or minimize use-related hazards found during the context of implementing, HF Cognitive developmental findings direct presented showing improvements.

D. **Verification Tests with Systems Engineering** HF testing tests show that the final finished effect occurs interface will improve the possibility of the user being used safely and efficiently by expected users for potential developments in the anticipated use context. Two kinds of studies on HF validity exist: HF Designed to simulate and HF Calculated validation.

- Simulation model Applied Sciences Evaluation Experiments
- Verification Tests of Human Elements Internal

E. **Human Factors Knowledge Task Studies** A research to test the participant's comprehension of these details (Knowledge Role Study) is necessary for the service disclosed in the labels or labeling of a mixed product to be a critical task for both the secure and efficient use of a product.

Implications of Method

A. Considerations for the submission of human factors mix product Analysis Results

i. Products being used in the healthcare setting

ii. Hybrid items which have a portion of the system where the data on human factorsmust be requested.

B. Design Improves Considerations Following HF Validation

C. Human Factors Analysis Details in Combination Product Systems for Inquiry

D. HF Studies Analysis and Some Marketing Application Marking

Applied Sciences Interaction and Significant Therapeutic Production Levels Trials As step of the procedure of product development controls, HF tests of a hybrid product is carried out. An acceptable HF implementation software would increase the possibility that perhaps the user experience of combination product is safe and efficient for usage by boththe intended customers, applications, and conditions of its use.

5.1.1.7 Standards of Premarket Pathways for Combination Products[13]

FDA on the standards for the pre-market examination of mix merchandise, and how it is proper to survey the kind of pre-market accommodation.

I. Combination product status and interaction with FDA

Basic fundamentals for engaging with Regulatory authorities The Lead Center is the main

touch point for a partner and normally the focal point for the Organization to presentthe opinions of the FDA to the donor. The lead community's pre-market cycles and conventions are open and can be utilized by supports, including pre-accommodation meetings and different strategies for getting contribution from the client.

II. **Basics of premarket regulation of combination products** When they are component elements of a combination product, medications, instruments and biological products maintain their distinct regulatory identities. Combination products include a different group of medicinal products that can be protected by specific regulation criteria.

III. **Pathway accessibility and related contemplations** Pathways accessible, and prerequisites for having such course choices, for mix items dependent on their PMOA.

A. Device-led combination products

As described earlier, section of the Assessment Made described different facets of mixed products control. The law represents, inter alia, the broad accessibility for device-led hybrid items in the De Novo classification, PMA and 510(k) pathways.

1. **Application for Premarket Approval (PMA)** PMA certificate is needed by the FDA until it is conceivable to lawfully sell essentially all gadgets that are class III. To consistently to get that drug the gadget drove mix item is protected and effective in its arranged use, which FDA suggests that PMA contains suitable better torment results.

2. **Demands for De Novo Identification** By applying area 513(f)(1) of the FD&C Act, instruments or even an uncommon kind not expressly ordered by the FDA generally on-premise of models set out in article 513(a)(1) of the FD&C Act will naturally be recognizedas Class III, however, it could be sorted by De Novo grouping measure as Class I or ClassII.

3. **Premarket Notification (510(k)) Submissions** A clearances basis to 510(k) (considerable comparability between a current contribution or a first item) varies from that of the PMA to De Novo endorsement prerequisites. The 510(k) survey prerequisites are practically identical, though the PMA nor De Novo assessment rules depend upon fair- minded proof of security and adequacy. In any case, the ideas of protection and adequacy include the significant

comparability

B. Drug-led combination products

For either a medication drove blend gadget, a NDA or ANDA is typically the necessary advertising approval course. This survey portrays the Agency's present deduction additionally on the utilization of NDA and ANDA courses for drug-drove mix medicationsto get advertising approval.

1. **New Drug Application (NDA)** In particular, an NDA was its required pathway for drug-driven combination products besides the generic variants of the drug-driven combination products already licensed, The NDA for just a medication-driven combination product shall include, inter alia, a proof of the safety and efficacy of the drug in the circumstances prescribed, advised or indicated in the present case.

C. **Combination goods that are biologically-led** Most biological goods are licensed for a "biologic" or "exchangeable" medicinal material in either section 351(a) of a BLA (i.e.a "hold" BLA) either section 351(k) of a BLA by one of the two BLA paths referred to in section 351 of a Public Health Service Act (PHS Act).

1. **Biologics License Applications (BLAs)** Sent in consistence with Section 351 (a) In request to be authorized, its physiological material should be shown to at any point be solid, unadulterated and intense, and the office where even the biomedical material is prepared, taken care of, stuffed or handled ought to in this manner hold fast to severe proposed to ensure that it discovers harmony, clean and amazing. A hold prerequisite has become a BLA mentioned comparing to article 351(a) of that equivalent PHS Act, since then the gathering facilitator all the data and realities expected to show that if these necessities are met.

2. **BLAs for biological products that are bio-similar and interchangeable Pursuant to Section 351 (k), submitted 422.** Under area 351(k) of the PHS Act, a truncated permit pathway is needed for items discovered to be bio-similar to or tantamount to an FDA-authorized organic reference item.

5.1.1.8 Spanning FOR DRUG-DEVICE AND BIOLOGIC-DEVICE COMBINATION PRODUCTS[14]

Spanning of New Drug Applications (NDAs) or Biologics License Applications (BLAs) for single organization or co-bundled half breed items for drug inserts and biologic gadgets, including.

- Bridging details pertaining to a hybrid product that hires a particular component of the system or components with the same component or components of the drug as the planned combination product
- Bridging of details related to a hybrid product utilizing a particular component of the substance or components with the same component or components of the system as the planned combination product.

I. Developing an empirical method to define knowledge gaps in intended to notify a trying to bridge and utilizing strategy

It is an essential undertaking for candidates to create a process that recognizes where knowledge gaps can occur in a joint product development program.

Stage 1. Distinguish all varieties among an and b mix items and consider the potential impacts of individual and joined contrasts on the mix item insurance and execution profile.

Stage 2 Identify current data for the blend item b (for example data acquired or created by preliminaries and trial of the proposed blend item itself) and liken it with the models for the wellbeing and adequacy accommodation required for endorsement.

Stage 3. Characterize and examine how current data on the blend item an ought to be crossed over and utilized to encourage the acknowledgment of the mix item b, observing the components in sync 1 and of the information previously got in sync 2.

II. Trying to bridge frameworks while optimizing them

A. Bridging from just a treatment produced in a pre - filled needle to even a medicine manufactured inside of an automated injection system inside an IND

Step 1. The discrepancies between the first and second presentations are defined by the claimant. The key distinction is the adjustment in the constituent portion of the unit createdby adding an auto injector to the mixture product of the PFS.

Step2. In tandem with the presentation of the auto-injector, the patient has not yet generated evidence directly for the medication and would thus have to either exploit current information or generate additional supporting details.

Step 3. For the PFS presentation, the applicant performed phase 3 tests. studies have givenPK data, non-clinical data, toxicity, safety and efficacy.

C. Convergence combined product details and uses a certain system paired with quite a specific medication

Step1. Combination Device A, which was endorsed by the FDA in the NDA and requiresa prefilled drug cartridge connected to the metered-portion inhaler, was recently deliveredby the inquirer.

Step2. Any data for Combination Product B has not yet been delivered by the petitioner and would subsequently need to either misuse existing data on the constituent segment of the gadget or create new subtleties

Step3. The petitioner concludes that the interface of the blend items An and B is the equivalent and that there is no change between the utilizations and conditions of utilizationof the items.

5.1.1.9 Specialized Considerations for showing the dependability of Emergency-Use Injectors Submitted under a BLA, NDA, or ANDA

Crisis use injectors sold as a pre-filled single-element mix item or as a co-bundled mix item with the crisis use drug. These medications are put available as mixture items doled out to the Center for Drug Evaluation and Research (CDER) or to the Center for Biological Evaluation and Research (CBER) under an approved NDA, ANDA, or BLA approval.

I. Administrative system

Mix items are dependent upon 21 CFR Section 4, which sets down rules for blend items as indicated by existing great assembling practice (CGMP).Part 4

Under the less difficult technique depicted in 21 CFR 4.4(b), makers of prescription item framework mix items, of the sort subject to this direction, which consent to the particularsof both the medication CGMPs and the gadget QS guideline as per the worked on approach characterized in 21 CFR 4.4(b), by creating and executing a CGMP working framework higher consummation with the medication CGMPs and the referenced assurances of the QS gadget, will

follow the determinations of both the medication CGMPs and the gadget QS enactment as per this rule.

- 21 CFR 820.20 Duty of the board
- 21 CFR 820.30 Design controls
- 21 CFR 820.50 Purchasing controls
- 21 CFR 820.100 Corrective and preventive advances
- 21 CFR 820.170 Installation
- 21 CFR 820.200 Servicing.

II. Creation of reliability reviews including product suggestions with marketing authorization applications

The achievement of the requisite durability specification is dependent on experience of the combination product's design, manufacture, and use.

1. Inputs of design and outputs of design required for ensuring reliability
2. Description of Emergency-Use Requirements of Injector Reliability
3. Study of the Fault Tree
4. Checking of Reliability
5. Absolute Efficiency of the product life cycle

III. Reliability report format considerations

The unwavering quality report ought to be given in the accompanying arrangement to advance the information appraisal:

Table 5.2 Reliability Of Emergency-Use Injectors Submitted Under A BLA, NDA Or ANDA.

Section	Content
1	The Combination Brand Classification • Drug Type • Indications for Use • Technological and Practical Overview of Emergency-Use injector • Design Inputs and Design Outputs Required for reliability
2	Specifications of Emergency-Use Injector Efficiency
3	Study of the Fault Tree
4	Check Schedule and Data for Reliability
5	Material Life Cycle Complete of Reliability Strategy

6	Conclusions
7	Appendices Containing Details Endorse Reports or Threats

We demand that the data be utilized with other framework constituent part data found in eCTD module 3.2.P.7 when sending this data to an NDA or BLA.

5.1.1.10 Requesting FDA feedback on Combination Products[15]

A mix item is assigned to an association community that will have selective authority over the premarket examination and authorization of the blended item. Under segment 503(g) (1) of the FD&C Act (21 USC 353 (g) (1)), the task to the lead center of a mix item depends on the assurance of the constituent part of the mix item's essential method of activity (PMOA).a lead place for a premarket survey of the mix item additionally has the lead for the post- market guideline.

I. Best Practices Regarding Interactions Between FDA and Sponsors of Combination Products

A. Support Best Practices

- Submissions for a Combination Product
- Clear and Appropriate Questions.
- Comprehensive Rationale and Supporting Information.
- Communications Through the Identified FDA POC

B. FDA Best Practices

- Notifying Sponsor of the FDA POC.
- Engaging Relevant Expertise,
- Consolidated, Aligned, and Reliable Feedback.

II. Techniques of reviews with combined products increases

A. Application-based Mechanisms

Combination products are also equipped with application-based frameworks for communicating with the FDA that are available for medications, computers, and biological products.

Details to include when seeking input from a framework on a drug combination On the combined package lead by a drug and biological product containing a constituents portion of the device

- Description of the device, design diagram or other illustration,
- defining components that are part of the device,
- If the hybrid product includes a portion of the device that is a cleared or approved device to be cross-referenced by the sponsor, mark the application or submission number for the device already cleared or approved.

For a device-led combination product

- Details defining and explaining the constituent part(s) of the drug and/or biological product, including, if appropriate, the chemical name, proper or existing name and structure,
- The route of administration and/or dosing information for the component(s) of thedrug and/or biological substance and the route of administration and/or dosing information.

B. Combination Product Agreement Meetings (CPAMs) CPAMs are meant as a way to achieve consistency and assurance for sponsors (in addition to application-based mechanisms) and are required for hybrid items for which the designation of the lead is transparent.

1. Details to use when seeking input via a CPAM on a hybrid product

Product Information Sponsors

- Should also include the title of the substance, the definition of total mixture drug and the component parts, the declaration of use guidelines and, where relevant, their method of exposure and high dose detail.
- Their commodity must be known as a hybrid product.

2. Submitting a CPAM Request CPAM

- To be sent to the drug combination lead base using procedures listed in Table 1 below;
- In the covering letter, define the application as a 'Pairing Commodity Arrangement Meeting
- Provide the complete information described in Section IV.B.1 above, so that FDA can assess whether a CPAM is the most efficient mechanism for interaction, coordinate between

centers, and ensure that FDA has sufficient information to evaluate the agreement proposal(s).

Table 5.3 Submission Process for CPAM Requests.

Lead Center	Combination Product Application Type	CPAM Request Process
CBER	IND, NDA, BLA, ANDA	Send the CPAM request • to the CBER Information Control Panel or electronically; • Submit the submission for CPAM to the relevant review division; State the amount of the document, if necessary,
	IDE, PMA, 510(k), De Novo, HDE, PDP	Send an e Copy 25 that is true to CBER Document Control Center. Stipulate, if necessary, the submission amount and in covering letter.
CDER	IND, NDA, BLA	Submit the letter for CPAM: • Digitally or even to the CDER Paper Management Center;23 • Send the application for CPAM to the relevant review division; and Type the submission numbers throughout the covering letter, if necessary. 24
	ANDA	Send a CPAM application if the ANDA has still not been submitted to the FDA: • To the CDER New Generation Partnership Platform digitally. State the amount of a submission
CDRH	IDE, PMA, 510(k), De Novo, HDE, PDP	To just the CDRH Report Operations Center, send a correct eCopy25. Stipulate throughout the personal statement the submission number, if relevant.

C. Use of Application-based Mechanisms, CPAMs, and Dispute Resolution

i. Issues Appropriate for Application-Based Mechanisms.

ii. Issues Appropriate for CPAM

iii. Issues Appropriate for Dispute Resolution/Appeal Through the Lead Center's Dispute Resolution or Appeals Process.

5.1.2 POSTMARKET COMBINATION PRODUCT

5.1.2.1 Entries for present Approval alterations on a Combination Product affirmed under a BLA, NDA, or PMA[16]

Its documentation remembers rules for either the essential guidelines for the business and FDA staff to choose the measure of showcasing accommodation that may be required for present endorsement alterations on a blended item as determined in 21 CFR 3.2(e)approved under a solitary advertising application, for example, a Biologics License Application (BLA), a New Drug Application (NDA) or maybe an Application of Pre- market Approval of Applications (PMA).

Which distributions delivered by the Center for Biologics Evaluation and Research (CBER), its Center for Devices and Radiological Health (CDRH), the Center for Drug Evaluation and Research (CDER), and the Combination Products Office are enlarged by such a rule (OCP).

Form of application to be submitted to an approved combination product before making a change

Diverse constituent parts structure a mix item. As a medication, framework, or organic item, these constituent areas keep up their administrative personality. Tables are introduced in this archive to commonly coordinate the comparing post-market entries for changes to aconstituent part of a mixed substance.

The following steps explain the procedure for deciding the form of submission to be made for a post market adjustment to be made to component of a combination product licensed under a BLA, NDA, or PMA.

1. Classify the kind of pre-market application that used secure the mixture product's approval (NDA, BLA, or PMA).
2. Define the type of request for post-approval which, when the component part(s) were marketed as a hold commodity, would normally were already submitted for amendment(s).
3. Where even the initial request type was used for the authorization of the mixture product,
4. In selecting the right post-approval modification submission form for hybrid item, usethe figures below as guidelines.

Table 5.4 provides the forms of NDA or BLA submissions to be made as part of a combination package accepted through an NDA or BLA while making a modificationto a device.

<table>
<tr><td colspan="2">If a Stand-Alone Product Licensed and under PMA were also the Device Component and the move would have needed subsequent notification</td><td colspan="2">If a Stand-Alone Product Licensed under a PMA have been the Device Component as well as the move might have required subsequent application</td></tr>
<tr><td colspan="2">PMA Original</td><td colspan="2">NDA/BLA Original</td></tr>
<tr><td colspan="2">PMA Committee Complement (Current obvious sign, backed by new clinical evidence and initial clinical trials data, with no other modifications to the component countries)</td><td>Prior Approval (Efficacy)</td><td>Supplement</td></tr>
<tr><td>PMA 180-day Supplement
• Design
• Manufacturing site change
Labeling
Change Including nomenclature</td><td>Measures backed through restricted reliability and validity knowledge (i.e., clinical bioequivalence or bioavailability data)
Changes to the manufacturing site that may not require any health evidence
Major change in labeling that would not apply for a Specific PMA Substitute - Improvements being carried out, doesn't really modify the definition and therefore does not require changes in style</td><td>Prior Approval Supplement (Manufacturing) (With or without labeling changes)
Prior Approval (Labeling)</td><td>Supplement</td></tr>
<tr><td colspan="2">Supplement to PMA Real-Time (Plan or naming change that doesn't need clinical information and for which the information gave fall inside just a single logical control, e.g., electrical designing, microbiology, or disinfection)</td><td colspan="2">Prior Approval Supplement (Manufacturing or Labeling)</td></tr>
<tr><td colspan="2">Note of 30-days (Manufacturing process or method change only)</td><td colspan="2">30-day Changes Being Effected</td></tr>
<tr><td colspan="2">Special PMA Supplement - Changes to also be introduced</td><td colspan="2">Changes to also be introduced</td></tr>
<tr><td colspan="2">PMA Periodic Report</td><td colspan="2">Annual Report</td></tr>
<tr><td colspan="4">*Time frames including collaborative FDA-industry processes would be those from the NDA/BLA</td></tr>
</table>

Table 5.5 Form of PMA Application for Improvement in the Component of aBiological Product/Drug Component of a Combined Product Licensed to compliance with the PMA.

When a Stand-Alone Biological Product/Drug Licensed and under BLA/NDA was the Biological Product/Drug Constituents Part and the move might have involved the subsequent submission		**Send Biological Product/Drug Modification Details Utilizing This Kind of PMA* Request only for Combination Product**
(Section 505(b)(1) or (b)(2))) BLA Initial; NDA Initial (A different chemical drug, new pharmaceutical component or development stage containing novel diagnostic innovations and different clinical trials data)		**PMA Original**
Prior Approval Supplement – Efficacy	Latest obvious sign, backed with modern clinical evidence and initial preclinical data, with no other modifications to the component sections,	**Panel-Track Supplement**
	Similar suggestion of a drug/biological manufacturing process transition involving clinical data	**180-day Supplement**
Prior Approval Supplement – Manufacturing	Change throughout the development of drugs/biological products that only require efficacy or solubility of medical studies	**180-day Supplement**
	Manufacturing of drugs/biological products and subsequent labeling improvements that do not include some kind of medicinal or preclinical (animal) evidence	**180-day Supplement or Real-Time Supplement**
Prior Supplement to Clearance- Marking		**180-day Supplement or Real-Time Supplement**
30-day improvements that are being introduced (Manufacturing process or method change only)		**PMA 30-day Notice**
Changes Being Effected (Manufacturing or Labeling)		**Special PMA Supplement - Changes Being Effected**
Annual Report		**PMA Periodic Report**

Illustrations by type of Change being made

Based mostly on submission type used to receive the authorization of the combination product, the forms of submissions that such modifications may entail are listed. These guidelines are based on the applicable legislative and regulatory requirementsand the relevant policy documents for CDER, CDRH, and CBER.

1. Any improvements in the component portion of the combination product devicetypically

involve new preclinical and clinical evidence to confirm protection and efficacy. In general, for all other modifications that do not affect the primary mode of operation, choose the submission form corresponding to the type of application used to receive the hybrid product's approval

a) Initial PMA
b) Initial NDA
c) Initial BLA.

2. Adjustments in the substance of the product of a product constituent, the productive capacity of the product of the product constituent, standards of quality, machinery or facilities influencing the controlled release or molecular weight of a drug or may have a substantial potential to severely influence a module's identity, strength, performance, purityor toxicity. Generally, for each other change, use an application form referring to the particular application used to obtain the approval of both the mixture item.

a) Baseline Clearance Contributes with NDA
b) Complement to BLA Previous Proper authorization
c) Supports to PMA 180-day Authorization.

3. Updated chemical properties of the representative component of the unit Equipment or applications Alteration of the subjective component and other layout Adjustment of components of the unit. In order to provide fair assurance of the safety and efficacy of the modified device constituent component, only new preclinical research and/or restricted confirmatory clinical evidence is required.

a. PMA 180-day Complement
b. Additive to BLA Forward Authorization
c. Complement to NDA Forward Authorization.

4. Actions in the component, manufacturing process, quality management, equipment, facilities or responsible staff of the biological product which have a significant potential to get an adverse impact on the product's identity, strength, quality, purity or potency.

a. Supplements to BLA Forward Authorization
b. Complement to NDA Forward Authorization

c. Supplementation to PMA 180-day.

5. Changes in the indication or demographic of patients (without any other improvement in the mixture substance itself or in any of its component components, with the exception of relevant labeling changes) requiring extensive clinical data to offer fair evidence of the safety and efficacy of the change, but no or quite limited new preclinical studies.

a. PMA Committee
b. Supplements of NDA Specific Authorization
c. Complement of BLA Forward Authorization

5.1.2.2Current Good Manufacturing Practice Requirements for Combination Products[17]

Current Good manufacturing practice (CGMP) principles delivered by the FDA on January22, 2013, for crossbreed items (last standard) (21, Section 4 of the Code of Federal Regulations (CFR)). While CGMP guidelines were in power to set determinations for medications, instruments, natural items, and human cells, tissues, and cell and tissue-baseditems (HCT/Ps), before the issuance of the last standard.

I. Background

A. combination product A combination product is a product consisting of two or more distinct types of medical products (i.e. a combination of one pharmaceutical product, one system, and/or one biological product). 'Constituent parts' of the mixed product are referred to as the medications, instruments and biological components used in the combination products.

B. Quality and Current Good Manufacturing Practice

Ensure that quality medications, biologics, instruments and combination products that reliably conform with acceptable standards and specifications are eligible. A system of minimum standards to help ensure product safety is provided by the medication CGMP and application QS regulations, as well as the CGMPs for biologics and existing good tissue practices for HCT/Ps. Systems to ensure adequate design, inspection, and supervision of production processes and facilities are the central specifications contained in these regulations.

C. Outline of the last standard

1. Synopsis of the Final Rule

After they are blended, the constituent pieces of a half and half substance keep up their lawful power (as a medication or framework, for example). This rule alludes to a "CGMP working framework" to mean the working framework inside a foundation planned and acquainted with meet and adjust with the current norms of good modern practice.

appropriate to the advancement of a crossover item. The last principle on CGMP prerequisites for blend items applies to all mix items.

The determinations of the CGMP for constituent pieces of cross-named crossover items made totally in various offices are equivalent to that which would happen if thoseconstituent parts were not piece of the mix item.

Table 5. 6 FDA Combination Product Regulations: Streamlined Approach.

COMMON GMP ELEMENTS		
Device QSR Requirements	**Drug CGMP Requirements**	**Biologic GMP Requirements**
§820.20: Management Responsibility §820.30: Design Controls § 820.50: Purchasing Controls § 820.100: CAPA §820.170: Installation §820.200: Servicing	§211.84:Testing/endorsement/dismissal of comp. § 211.103: Calculation of yield §211.132:Tamper-apparent bundling § 211.137: Expiration dating § 211.165: Testing and delivery for circulation § 211.166: Stability testing §211.167: Special testing necessities	§ 600.2-3: General Provisions §600.10-15: Establishment Standards §600.20-22:Establishment Inspection § 600.80-81: Post Marketing Reporting § 600.90: Waivers § 610.1-2: Release Requirements § 610.9-18: General Provisions § 610.20-21: Standards Prep./Limits of Potency
		§610.40-48: Testing Request Communicable Disease
		§610.50: Date of Manufacture
		§610.53:Dating periods for authorized Bio. Items
		§ 610.60-68: Labeling Standards

		§ 1271: Human Cells, Tissues, and Cellular &Tissue-Based Products

2. **Documentation of CGMP Approach** – The quality framework report of the manufacturing plant ought to depict the CGMP working framework for the mixed product(s) delivered at that office, and toward the beginning of an examination, the organization should impart this detail to specialists.

The drug in the Common Technical Document zeroed in on CGMP or framework QS control. See e CTD Professional Conformance Reference, Section 3.3.2.14 For PMAs, the CGMP technique ought to be accounted for in the creation part of the PMA for more data on situating inside the CTD (the assembling module for a secluded PMA). smoothed- out approach. In premarket entries, the CGMP approach ought to be distinguished for each significant office. for NDAs, BLAs, and ANDAs, the CGMP approach.

D. The part of the lead community and other Agency segments

A mix item is assigned to an Organization place that would have an essential position (for example the lead) for premarket examination and requirement of the blended item. Under segment 503 (g) (1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(g)), the allotment of a consolidated substance to a lead community dependson an estimation of the constituent part of which is given by the PMOA of the blended item. On the off chance that the PMOA of a gadget organic item mix item is inferable fromthe natural item.

Assembling organizations can likewise inform the Office of Combination Products (OCP)for direction, where appropriate, in deciding reasonable channels of correspondence (eventhose in the number one spot base), tending to considerable issues, or in any case advancingcontacts with just as planning with the Department, including the Office of Regulatory Affairs, even among the components including its Organization (ORA).

III. CGMP Enforcement Specific Requirements

Extra necessities may apply including the requirement for premarket entries because of changes to item configuration, proposed use, or assembling.

A. Demonstrating compliance The last guideline portrays two structures for co-bundled and

single-substance mix item providers to exhibit consistence with the material CGMP necessities. The Department expects to apply the term 'illustrate' to Part 4 for the motivations behind managing the hidden CGMP guidelines alluded to in 21 CFR 4.3. Makers should exhibit consistency with each relevant CGMP prerequisite for constituent parts and mix items.

A maker applying a smoothed out approach isn't needed to show similarity with the specific states of the non-base assortment of determinations other than those expressed in 21 CFR 4.4(b) (for example the maker will exhibit consistence with the important medication CGMPs in addition to the six determined arrangements of Part 820 for a medication CGMP-based smoothed out approach, as relevant, yet the producer doesn't have to show consistence with the other explicit arrangements to some degree 820).

B. Investigational products Part 4 An investigational medication for use is dependent upon the administrative prerequisites set out in 21 U.S.C. 351(a)(2) in stage 1 preliminary (B). What's more, the creation of such medicine is prohibited from consistency with the enactment found in Sections 210 and 211 and is consequently in this way excluded from the production of an investigational mix substance containing a segment of the medicationfor use in stage 1 preliminary. All things being equal, this exclusion doesn't allude to a testclinical treatment substance or part as long as it's been delivered openly to be utilized by or through the advertiser of stage 2 and stage 3 preliminaries, nor does the exception stretch out to a remedy item which has been effectively promoted.

C. CGMP requirements apply to a product or facility

1. CGMP Requirements Predictive validity To Even a Material Which constitution to the new proposal sets forth the CGMP requirements are applicable to the problem of hybrid goods, suggesting, for instance, that even an over-the-counter (OTC) combination brand are applicable. Except combined products that contain CGMPs would meet the over-the- counter (OTC) price compare but cooperate with adulterate marketing specifications including its CGMP device.

2. These steps must be pursued by producers if they are desired. Such terminology suggests that companies are given the ability to record the rationale for deciding that sucha measure or

strategy is not suitable or required for the particular commodity or development operation performed by them.

3. A plant that delivers a segment of a mix item or a full mix item will follow the arrangements of the CGMP pertinent to any creation cycle that happens at that specific plant. What's more, despite the fact that the proprietor isn't effectively intrigued by the creation, the mix item proprietor holds extreme obligation regarding the item. Makers are one method for guaranteeing that upgrades to a constituent variable are straightforward to the producer or proprietor of a cross-breed item.

D. **Control of changes to a combination product** Manufacturers of single and co- packaged mixed products must make agreements with their retailers, suppliers and contractors to obtain notification of changes in the product or service.

IV. CGMP necessities determined in 21 CFR 4.4(b)

A. Arrangements from the gadget QS guideline determined in 21 CFR 4.4(b)(1)

Device QS regulation that producers of single-ended and founder hybrid goods that containa device component must show conformity with the CGMP drug-based simplified methodology defined under 21 CFR 4.4(b)(1), including relevant considerations for the implementation to pharmaceutical formulations of these device QS regulatory specifications.

1. **The board obligation (21 CFR 820.20) Requirements** The administrative arrangements of the CGMP and medication guidelines set down models identifying with duty regarding the executives, and the Agency has likewise given rules on this matter. All things considered, there have been explicit prerequisites in 21 CFR 820.20 that are regularly not unequivocally tended to in the measures of the CGMP drug and the producer of a mix item which incorporates the segment a piece of the gadget should guarantee that the part is tended to needed under 21 CFR 820.20 are fulfilled.

2. **Configuration controls (21 CFR 820.30)** Design controls that identify with single-substance or co-bundled blend items which incorporate a segment of the framework to which they are subject. Configuration checking rehearses ensure that no unsafe cooperationhappen between the constituent parts and guarantee that the joint use brings about a solid and

beneficial half and half item that proceeds as envisioned.

3. **Buying controls (21 CFR 820.50)** Purchased products and administrations as characterized in 21 CFR 820.50 should be managed by makers of single-substance and co- bundled blend merchandise which incorporate a framework constituent part.

4. **Remedial and Preventive Actions (21 CFR 820.100)** Manufacturers of co-bundled or single-substance mixture products having a framework segment will, where essential, create and hold conventions for the usage of CAPA measures for issues happening at their offices.

B. Provisions from the drug CGMPs specified in 21 CFR 4.4(b)

Producers of co-packaged or single-entity hybrid goods having a system part shall, where applicable, lay down and maintain instructions for the implementation of CAPA measures to problems occurring at their facilities.

1. **Checking and freedom or forswearing of parts, compartments, and seals for drug items (21 CFR 211.84)** Components, cylinders, and terminations of medication items ought to be checked in consistence with 21 CFR 211.84. A piece of a therapeutic item is any fixing proposed for use in the assembling of a restorative item, even fixings which don't exist in a therapeutic item.

2. **Count of Yield (21 CFR 211.103)** As characterized in 21 CFR 211.103, genuine yields and rates of possible yield for the medication constituent part(s) of a blended item should be determined.

3. **With over clinical drug drugs Interfere bundle rules (21 CFR 211.132)** OTC crossover substance producers will conform to the determinations of 21 CFR 211.132. Alter apparent bundling and stamping making buyers aware of these wellbeing parts of theitem's bundling are the fundamental controls. These controls are critical to help incrementthe nature of the bundling of OTC mix items and to guarantee the wellbeing and executionof OTC mix items

4. **Termination dating (21 CFR 211.137)** It guarantees that drug items (the parts of the medication on account of half and half items) adjust with the pertinent recognizable proof,

force, consistency, and virtue necessities at the hour of utilization by requiring an expiry date on the item naming.

5. **Testing and delivery for dispersion (21 CFR 211.165)** In drug item preparing and quality administration, testing and delivery for conveyance are significant. 21 CFR 211.165 requests that legitimate research center assurance of adequate consistency with the last necessities (counting the distinguishing proof and strength of every dynamic fixing) be completed preceding dispatch by each clump of the medication item.

Dependability testing (21 CFR 211.166) 21 CFR 211.166 incorporates a program for exploration to decide the steadiness properties of medication items. Moreover, 21 CFR 211.166 spreads out the necessary components of the test plot, including enormous example components, stockpiling courses of action for tests held for handling, and differentcomponents relating to the system and recurrence of testing.

6. **Extraordinary necessities in regards to assessment (21 CFR 211.167)** 21 CFR 211.167(b) needs satisfactory screening of ophthalmology creams which assess understanding with the norms for the presence of unfamiliar things and of crude or grating substances, and 21 CFR 211.167(c) requires fitting research center testing of directed measurements structures to guarantee congruity with both the delivery rate model.

7. **Save tests (21 CFR 211.170)** Reserve tests are expected to help in keeping up the quality and adequacy of the conveyance of half and half items, as they are with prescriptions and natural items. For prescription constituent areas of blended things, the save testing measures of 21 CFR 211.170 should be satisfied.

C. Blend items that incorporate organic items and HCT/Ps

The producer of a blended item containing a natural item or an HCT/P will follow the conditions that would apply to the organic item or HCT/P in the event that it was not a piece of the mix item, as material under Part 4 of the CGMP medication and framework QS guideline prerequisites.

1. **Conforming to CGMP necessities for natural items** It, in reality, worth recalling that

maybe an organic item represented under area 351 of the PHS Act is valid, by definition, medication or a gadget. Accordingly, notwithstanding the arrangement of parts 600 to 680,the organic item is by all accounts either delicate to a CGMP drug or to the QS guideline of the gadget, independent of whether the natural item shapes part of the blend.

2. **Conforming to CGMPs for HCT/Ps** As a medication, gadget, or natural item, an HCT/P that probably won't be represented altogether under area 361 of the PHS Act and Part 1271 is likewise controlled. In view of if the thing is administered as a medication, gadget, or natural item, the medication CGMPs, gadget QS guideline, and the standards inparts 600 through 680 may apply to an HCT/P. 112 CGMPs and furthermore the CGTPs for HCT/Ps supplement one another.

V. Use of CGMP necessities to explicit kinds of blend items

That both medication CGMPs just as the gadget QS guideline are liable to kinds of blend items, all other examples are being utilized to focus on explicit CGMP touch points to CGMP guidelines showed in 21 CFR 4.4. (b). Especially

- Section A, a portrayal of a prefilled needle, ponders how to adjust with the necessities of the gadget QS guideline expressed in 21 CFR 4.4(b)(1) if a provideraccepts a worked on CGMP-based medication arrangement in light of its CGMP gadget.
- Section B, a medication-covered lattice model, considers worries for consistency with some gadget QS guidelines.
- Section C, an illustration of a medication eluting stent (DES), thinks about how toadjust with either the CGMP drug prerequisites characterized in 21 CFR 4.4(b)(2)if a provider accepts a shortsighted strategy zeroed in on framework QS guideline for its CGMP movement.

A. Prefilled needle

1. **Situation Description A medication producer** In a particularly pre-filled needle setting, maker A) plans to advertise a prescription. Producer An as of now has a medication name promoting license and plans to demand simply a prefilled needle exhibit showcasing approval. There'll be no significant enhancements to the prescription synthesis. Maker A will acquire off-the-rack needle parts from a retailer (Manufacturer B) that likewise supplies completed needle parts.

2. **Consistency with gadget QS guideline prerequisites** Manufacturer A will adjust withthe necessities of the gadget quality framework (QS) enactment expressed in 21 CFR 4.4(b)(1) in the wake of having picked to utilize the medication CGMP-based worked on an arrangement under 21 CFR 4.4(b)(1), as well as showing consistency with the medication CGMPs (1). This conversation gives extraordinary contemplations and activities to the half and half segment maker for any such condition.

   a) **21 CFR 820.20, Management Responsibility** Manufacturer An absolute necessityguarantee that its CGMP working framework exhibits consistence with the particular prerequisites in 21 CFR 820.20.

   b) **21 CFR 820.30, Design Controls** It is likewise the duty of Manufacturer A to assemble and actualize conventions for format control exercises and for drug blend. Producer An is the administrator of this case and makes the prefilled needle. Producer An is additionally obligated and for the needle progressed configuration program as a feature of the crossover thing, and furthermore holding in general duty regarding the needle configuration control exercises.

   c) **21 CFR 820.50, Purchasing Controls** Manufacturer An is relied upon to screen its purchasing rehearses, for example, those including needle parts, in consistence with 21 CFR 820.50.124 For instance, where needle barrels and unclogger materials are fundamental to guaranteeing that no unfriendly medication response happens.

   d) **21 CFR 820.100, Corrective and Preventive Actions** Manufacturer An is relied upon to create and hold CAPA methods for both the part of the combination. To guarantee that maybe the needle is stacked with both the correct amount of the medication, Manufacturer A has presented in-measure creation affirmation conventions to assess the outcomes from this check for any non-conformity.

   e) **21 CFR 820.170, Installation Managing** The prefilled needle won't be dependentupon establishment and adjusting necessities on the grounds that the gadget does exclude get together or upkeep rehearses.

b. Medication covered cross-section

1. Situation Description Manufacturer

A proposition for the promoting of medication covered plastic careful cross section Manufacturer An is permitted to sell the uncoated lattice available. Producer A requirements to cover the lattice at the site of the item's implantation with a medication to treat disease Manufacturer B is approved to put for the most part on market a restorative item for the regional government for the treatment of contamination just at the embed site of this class of gadget, not in an execution reasonable for a network covering. Producer A has built up a business companionship with Manufacturer B to utilize drugs and to make the data expected to guarantee the showcasing approval of Manufacturer A for the covered cross section. Producer B will create the medication plan for showering on the cross section, and the completed medication coverednetwork cost control will be delivered by Manufacturer A.

2. Consistency with QS guideline necessities

The encased texture thing is a mixed result of a solitary element under 21 CFR 3.2(e)(1). Therefore, Manufacturer An is delicate to both the medication CGMPs and the gadget QS guideline for this mix item. Producer An as of now showcases the unbleached lattice, has a current working framework dependent on QS guidelines, and plans to work and under improved on rough put together gadget is based with respect to QS guideline.

a) **21 CFR 820.30, Design Controls** That plan the executives' method for the medication constituent part of the consolidated gadget centers around guaranteeing that the medication covered lattice is secure and effective at the implantation site for the treatment of irresistible illnesses.

b) **21 CFR 820.50, Purchasing Controls** Shall be dependent upon 21 CFR 820.50, Producer An as of now has created conventions for checking buying/provider activities. Producer A will guarantee, as indicated by this standard, that satisfactory purchasing controls are created and held for Manufacturer B. To guarantee that Manufacturer An is alarmed, Manufacturer A can create buy concurrences with Manufacturer any progressions that may influence the exhibition of the mix item preceding Manufacturer B's usage of the changes.

C. Medication Eluting Stent (DES)

1. **Situation Description** In this situation, Manufacturer A was its client of a medication eluting

stent (DES) comprised of a medication covered stent. Maker B creates the dynamic drug segment (API or mass therapeutic material), Producer C delivers the silicone with which mass restorative fluid is blended for stent covering, and Manufacturer D delivers the materials utilized for the essential bundling of the medicine.

2. **Consistency with drug CGMP necessities** DES, as determined in 21 CFR 3.2(e)(1), is a solitary element combination item and is accordingly exposed to both CGMP item andQS framework guidelines. Maker A has effectively a CGMP internet browser arranged to conform to both the gadget QS enactment as a gadget producer however has picked to build up a gadget QS guideline-based worked on the answer for both the DES in consistence with 21 CFR 4.4.

a) **21 CFR 211.84, Testing and endorsement or dismissal of medication parts**, item holders, and terminations He DES purchasing control of Supplier A will likewise incorporate assurance of Supplier B as the provider of the mass medication item, Manufacturer C as the provider of the covering sap, and Manufacturer D as the provider ofthe fundamental bundling materials in consistence with 21 CFR 820.50(a)(a) (1). The obligations of Producer An under 21 CFR 211.84 apply to these various duties.

b) **21 CFR 211.103, Calculation of yield** The estimation of the yield ought to be completed when the use of the covering to the stent, including the arrangement of the covering, during all vital strides in the advancement cycle. Producer An is liable for the estimation of the yield at the necessary preparing stages at its processing plant, including the use of the DES covering and the DES bundling.

c) **21 CFR 211.132, Tamper-obvious bundling necessities for over-the-counter (OTC)** Human medication items lawful arrangement, in spite of the fact that they are not OTC items, ought not to stretch out to tranquilize eluting stents.

d) **21 CFR 211.137, Expiration dating** Manufacturer A can set the expiry date when the last combination part is numbered. The expiry date ought to be resolved based on data fromof the technique approval for the finished stuffed DES just as other time span of usability factors should likewise be considered on a case by case basis inside plan control.

e) **21 CFR 211.165, Testing and release for distribution** For production, development and lab processes, a specific explanation of all the experiments carried out on the DES as well as the approval requirements should be included in the report. In normal policies and procedures, a summary of each empirical evaluation must be planned and recorded. Here is an overall list of tests for drug-eluting stents.

- Personality
- Indications of deterioration
- Drug release rate (instant and/or time release rates)
- Material uniformity
- Kit Promise of Honesty
- Sterility
- The quiet operation
- Particle pollution
- Extra research, if necessary (including testing for polymer molecularweight, residual monomers, catalysts, other additives).

f) **21 CFR 211.166, Stability testing** The following concerns should be discussed in stability testing for the final DES product: quality, assay/chemical material, impurity/degradation materials, drug release rate, particulate matter, sterility, and integrityof the box.

g) **21 CFR 211.167, Special testing requirements** Manufacturer A is expected to perform or participate in DES research in compliance with 21 CFR 211.167(a) since this type of substance is claimed to be clean and pro.

5.1.2.4 Post-Marketing Safety Reporting For Combination Products[18]

Requirements for post-marketing safety reporting (PMSR) for combination goods released by the FDA on 20 December 2016 (81 FR 92603) and enforced in 21 CFR Section 4, Subpart B (subparagraph the "PMSR combination product final rule," "final rule," or "rule").

I. Regulation with Specific Criteria for Combine Substance PMSR

The final law of the PMSR hybrid product deals with combination products that are subjectto FDA pre-market inspection. 'Combination Product Applicants' and 'Constituent Part Applicants' are the individuals subject to the final rule.

- **Application Type-Based Reporting Requirements**. These criteria apply to both the Combination Product Applicants and the Constituent Part Applicants, on the basis of the form of submission for which the marketing authorization was given to the Combination Product or Constituent Part
- **Constituent Criteria for part-based documentation.** Component part-based disclosure requirements are applicable to those applicants for hybrid products or are concentrated upon on categories of components used throughout the combination product.
- **Information Sharing.** The law allows Constituent Part Applicants to share with each other any post marketing protection details they receive.
- **Submission Process**. The law defines how candidates for the Hybrid Commodity and Constituent Component must apply details about PMSR to the Department.
- **Streamlined reporting.** The rule offers means to satisfy certain reporting requirements together in the same report.
- **Records Retention.** The law determines what documents must be maintained by Mixture Component and Constituent Component Applicants and how long to hold them.

II. Specifications for protection monitoring Refer to myself when I'm a candidate fora combined product either Component Part Application

Each portion outlines the safety monitoring criteria relevant to the component parts of the hybrid products (i.e. the 21 CFR Part 314 drug specifications, the 21 CFR Parts 600 and 606 biological product requirements, and the 21 CFR Parts 803 and 806 device requirements) and the knowledge exchange requirements applicable to component Part Applicants in compliance with the Law

1. For All Combination Feature Clients and Constituency Component Applications,request variety disclosure requirements apply to

- NDAs/ANDAs are subjected to the specifications defined in 21 CFR Section3144 for safety reporting.
- BLAs are subject to the specifications defined in 21 CFR Sections 600 and 6066 for safety reporting.
- Device implementations are subject to the criteria for security reporting defined in 21

II. Explicit PMSR Requirements

A. Singular Case Safety Reports for Combination Product Applicants The last law of the mixture ware PMSR and this rule, ICSRs incorporate 15-day reports (see 21 CFR 314.80 and 600.80), five-day reports (see 21 CFR 803.3, 803.53, and 803.56), disappointment reports (see 21 CFR 803.50 and 803.56), and demise or genuine injury reports (see 21 CFR 803.50 and 803.56).

1. Fifteen-day Reports (see 21 CFR 314.80 and 600.80)

Mix items containing medication or organic segment constituent component are dependent upon fifteen-day revealing guidelines (see 21 CFR 4.102(b)(2) and (b)(3) and 4.102(c)(2)(ii) and (c)(3) (ii)). Fifteen-day records to be put together by candidates for halfand half things for:

- "Adverse encounters" which are "not kidding" just as "startling"
- Combination products sold in an ANDA, NDA, or BLA inside fifteen days fromthe date
- For crossover merchandise sold under a Device Application, as clarified beneath, inside 30 schedule days.

2. **Five-day Reports (see 21 CFR 803.3, 803.53, and 803.56)** Combination things involving a framework constituent part (21 CFR 4.102(b)(1) and 4.102(c)(1)(i)) are dependent upon five-day revealing guidelines. Mix item candidates to demand five-day reports for those mix items no later than five working days after the day on which the Combination Product Applicant gets mindful of by the same token**.**

- A notifiable occurrence for a blend substance "requires remedial measures to maintain a strategic distance from an unsuitable weight of critical general wellbeingharm"
- We (FDA) "have presented a composed solicitation for a [Five-Day] report" (21 CFR 803.53).

3. Breakdown Reports (see 21 CFR 803.50 and 803.56)

An example happens Applications for these mix items will submit breakdown reports no longer than six schedule days24 after the subtleties got by the petitioner has been gathered and in any case, realized that:

- "Fairly inferred"
- The object has fizzled

- The ware sold by the respondent, or a connected item.

4. **Follow-up Reports (see 21 CFR 314.80, 600.80, 803.56)** Follow-up checking standards require five days, and blended items require breakdown documentation. Checking necessities likewise apply to reports of passing and critical wounds documented by candidates for mixture items requiring promoting approval for blend item candidates under a gadget.

5. **Data on consolidated substance ICSR Used in intermittent wellbeing reports** There under blend item PMSR rule, customary detailing necessities for mix items advertised under an NDA, ANDA, or BLA (21 CFR 4.102(d)) (1). Where a specific half breed item incorporates a part of the gadget, the ordinary reports will incorporate a synopsis and investigation of the five-day and disappointment reports got during the intermittent security revealing cycle (see 21 CFR) (1).

6. **ICSRs of assortment merchandise for worldwide exercises or communications** The global blend substance occasion the executives rules are predictable with both the base administrative norms for clinical items, gadgets and natural items in certain circumstances (see 21 CFR 4.102). Besides, up to degree that it probably won't be should have been delivered inside FDA guidelines,

B. Those specific (Non-ICSR) Effect Occur PMSR Document Characteristics other than Candidates other than Marketing Authorizations

1. **Field Alert Reports (see 21 CFR 314.81)** For conveyed combination things containinga medication constituent part, field cautioning revealing rules apply (see 21 CFR 4.102(b)(2) and 4.102(c)(2)(i)). See additionally parts IV.C and V.A.3 underneath on FAR and BDPR checking to smooth out. Mix item Applicants for certain mix products should apply to the FARs the accompanying subtleties inside three working long periods of receipt.

- "[A]ny occurrence which permits the [product] or its marking to likewise be misconstrued for or twisted to another article," or "identified with any bacteriological tainting or to any significant substance, physical or other change or crumbling of the [product] appropriated"
- [A]ny default of at least one disseminated bunches of the [product] to follow the particulars

set down for both in the application.

2. Natural Product Deviation Reports (see 21 CFR 600.14 and 606.171)

Blend Product Applicants for these mix items ought to apply BPDRs for 'any occasion and subtleties identifying with an occasion identified with the item, including testing, bundling, wrapping, stamping or capacity, and for the maintenance or conveyance of the item, regardless of whether that occasion:

- A takeoff from current great assembling practice, material enactment, administrative norms, or existing necessities that can impact the quality, virtue, or strength of that item;
- An unordinary or unexpected event that can influence the assurance, virtue, or intensity of the item.

3. Revision and Removal Reports Correction and rejection documentation norms to allude to cross breed things including part of the framework (21 CFR 4.102(b)(1),(c)(1)iii) and 806.10). Mix Substance Claimant will demand change and withdrawal records for those blend items.

- In 10 working long periods of starting a change or withdrawal,
- "[R]educate the wellbeing hazard raised by the [product]"
- "[t]he infringement of a [FD&C Act] instigated by [product] that may represent a wellbeing hazard" (21 CFR 806.10).

C. Data Sharing Between Constituent Part Applicants

Information trade conditions reach out to Applicants of the Constituent Component (21 CFR 4.103). Under 21 CFR 4.103, the inquirer will share the accompanying data.

- no under 5 days after receipt;
- with the other Constituent Part Applicant(s) for a similar blend item
- A blend substanceoccurrence including passing or genuine injury as characterized in 21 CFR 803.3, or
- Adverse experience as characterized in 21 CFR 314.80(a) and 600.80; (a).

III. Method Requirements for candidates for combined products

A. Send information about the PMSR combination substance to the FDA Combination

product applications agree with the deadlines associated from all reporting forms, but for combination goods receiving market authorization under Sensitive To vibration Fifteen-day reporting under 21 CFR 314.80 or 600.80 must be submitted after 30calendar days than just roughly 15 calendar days (see 21 CFR 4.102(c)(2)(ii) and (c)(ii) and (c)(c)(2)(iii) respectively).

Table 5.7 Timelines for Various Combination Product PMSR Requirements.

Report Type	Timeline for Reporting
Fifteen-day Reports	ANDA, NDA and BLA mix products: no later than 15 calendar days from the date of receipt of the details by the claimant (see 21 CFR 314.80(c) and 600.80(c)). Device Implementation of combination products: no later than 30 calendar days from the date of acceptance of the details by the claimant (see 21 CFR 4.102(c)).
Follow-ups to Fifteen- day Reports*	ANDA, NDA and BLA mix products: within 15 calendar days of receipt of new knowledge (see 21 CFR 314.80(c) and 600.80(c)). Device Implementation of combination products: no later than 30 calendar days from the date of acceptance by the applicant of the latest knowledge (see 21 CFR 4.102(c)).
Five-day Reports	Not later than 5 working days after the date on which the claimant "will become aware" (see subparagraph 23) that a reportable event(s) needs remedial intervention to avoid an undue risk of significant risk to public health (see 21 CFR 803.53).
Death/Serious Injury/Malfunction Reports	Not less than period of 30 days from the date on which the claimant collects information and or becoming aware of the incident (see 21 CFR 803.50)
Supplemental/ Follow-up reports to Five-day/ Death/ Serious Injury/	Within 30 calendar days of the day that the applicant receives information (see 21 CFR 803.56)
Malfunction Report*	
Field Alert Reports	Within 3 working days of receipt of the information by the applicant (see 21 CFR 314.81(b)(1))
Biological Product Deviation Reports	As soon as possible but not beyond 45 calendar days from the date of acquisition of the details, it is fair to indicate that a reportable incident has occurred (see 21 CFR 600.14(c) and 606.171(c))
Correction and Removal Reports	Within 10 working days of initiating correction or removal (see 21 CFR 806.10(b))

B. Features to be used in PMSR assessments of combined substances

1. Standard Material to Sending Combination Product PMSR Reports PMSR reports to

Combination Products:

- Should include all the material needed for the sort of study under it applicable Regulations, including specific details on this product (including each component) (21 CFR 4.102).
- If the Integrated Device User verifies multiple types of information for the same event or device issue, the team reviews links to applicable PMSR reports, particularly generally leads PMSR reports, accordance with the lead center's tracking systems and guidelines.

2. Additional details to be used in combined commodity ICSRs. The knowledge category that effect Occurs Consumers require are mentioned in this report.

- The following material, including details on the constituent parts of the mixture device, should be given, irrespective of which component(s) might have been involved in the case.

3. Details to be used in the follow-up ICSRs You must follow the relevant legislation in order to decide what information to use in the follow-up ICSRs.

4. Details to be used in the Annual Safety Reports for ANDA/NDA/BLA Hybrid Items that provide System Constituent Component Covering Five-day and Malfunction Reports.

5. Relevant info to be used in non-ICSR Mix Commodity Reports (Document of Adjustment and Withdrawal, FAR, including BPDR)

5.1.3 Combination products of e CTD requirements (Dossier)[19]

By and large, drug or organic item data for mix medication and gadget item data and related designing and assembling data ought to be situated in similar eCTD segments that would give comparable data to the medication or natural item alone. This especially appliesto gadget constituent parts that likewise fill in as the medication holder conclusion framework. For instance, the M3 quality module ought to contain data on such gadgets' constituents in area 3.2.P.7. Strong documents for holder conclusion gadget constituents ought to be situated in area 3.2.R. For different sorts of gadget constituent parts that don't include a consistent area inside 3.2.P, the data ought to be put in 3.2.R. For instance, qualityinformation for an unattached laser would be in 3.2.R. Quality data on the blended item overall (not the different constituent parts) ought to be situated in 3.2.P with proper hyperlinks to 3.2.R. The accompanying suggestions ought to be trailed by backers and candidates for mix products.

5.1.3.1 General arrangement remarks

a. Utilization of eCTD headings: Adhere to eCTD headings as characterized in the FDA specialized detail Comprehensive Table of Contents Headings and Hierarchy.
b. Hub expansions: Do not utilize hub augmentations to make new components. Albeit thisis portrayed in the ICH eCTD detail and might be satisfactory in certain districts, it isn't worthy in any entries to FDA.
c. Leaf titles: As there are no-sub components allowed under 3.2.R while putting blend item records in this part, prefix the leaf title with "Gadget" as this will assist the analyst with separating mix and different classifications of documents.

5.1.3.2 Module 1, Section 1.2

To encourage the audit, a commentator's guide ought to be given in segment 1.2 introductory letters. The analyst's guide is independent from the introductory letter and referred to after the introductory letter. It ought to give a significant level outline (with reference joins) of the accommodation's substance and should list the area of data in the eCTD. 21 For instance, it ought to distinguish where sedate, gadget, furthermore, mix itemdata is found. Furthermore, the commentator's guide ought to recognize the area of data that can't be additionally distinguished inside the electronic configuration. This especially applies to the accompanying.

- Files that are not presently recorded as mathematical things in ICH and FDA particulars and direction archives (e.g., Comprehensive Table of Contents Headings and Hierarchy22). For instance, the commentator's guide ought to give reference connects to each document in segment 3.2.R.
- Sections which are rehashed using distinctive XML ascribes (for example <m3-2- p-drug item name = "Albuterol">; <m3-2-p-drug item name = "Dry Powder Inhaler">).

5.1.3.3 Module 1.1. Structures

Structure 356h ought to recognize all offices associated with the assembling and testing of the blend item (drug, gadget, drug-gadget mix). Likewise, see thing 4.a underneath for extra data in Section 3.2.P.3 Manufacture.

5.1.3.4 Module 3

a. Area 3.2.P.3 Manufacture Blend item fabricating applies to the whole mix item (e.g., drug-gadget mix) as per 21 CFR Part 4. 23 In Section 3.2.P.3 incorporate relevant gadget data relating to assembling or gathering of the completed mix item all in all. As appropriate, this part may hyperlink to remarkable gadget constituent assembling data in 3.2.R. I. Area 3.2.P.3.1 Manufacturer(s)

- For every office distinguish the sort of assembling and testing exercises that happen
- For every office that is dependent upon 21 CFR section 4, character whether it follows the mix item smoothed out assembling approach and recognize the base arrangement of guidelines (i.e., 21 CFR 211 or 820).
- Provide an itemized rundown of all assembling offices; what exercises happen at the site (e.g., gathering, filling, disinfection, testing, other); which constituents are at the site (e.g., the medication just, the gadget just, both medication and gadget). For the offices that have both the medication and gadget, distinguish which mix item working framework is utilized at the site.

ii. Area 3.2.P.3.2 Batch Formula (nm, df)

Utilize this part to depict just the medication segments and structure.

iii. Area 3.2.P.3.3 Description of Manufacturing Process and Process Controls (nm, df)

This segment would contain any submitted general portrayals/outlines. It might cross-reference to segment 3.2.R to help the assembling cycle.

- Management Controls
- Design Control, General
- Purchasing Controls
- Corrective Action.

b. Area 3.2.P.5 Drug Product Area 3.2.P.5 ought to as a rule be a component of a rehashed segment, as proper. The principal 3.2.P Drug Product area would be for the medication item (e.g., <m3-2-p-drug item name = "midazolam injection">. The second 3.2. P Drug Product area may be for the last mix item part discharge determinations that incorporate the particular prerequisites for the gadget constituent (for example <m3-2-p- drug item name = "midazolam pre-filled syringe">). These details ought to depend on the gadget configuration move

information (see configuration control data) and should connection to the supporting e CTD information segment; e.g., in segment 3.2.R.

c. Area 3.2.P.7 Container Closure System Keep on utilizing this segment for gadgets that fill in as essential or optional compartment conclusion. Kindly allude to FDA direction on Container Closure for extra information.24 This segment may connection to area 3.2.R as fitting for gadget constituent testing.

d. Area 3.2.R Regional Information This segment might be utilized for gadget designing plan documentation and account clarifications that are not in any case given in Section 3.2.P.7. Instances of the data incorporate the accompanying:

A. Configuration Input Requirements
B. Configuration Output Specifications (e.g., gadget depiction, drawings, determinations, bill of materials, and so forth)
C. Plan Verification Plan/Summary Report and supporting information (e.g., programming, electromechanical conformance, seat testing, biocompatibility)
D. Plan Validation Plan/Summary Report and supporting information (e.g., execution testing, account conversation of the materialness of information gave in Module 5).
E. Danger Management File
F. Detectability Matrix

Note: Section 3.2 R doesn't accommodate subordinate areas. Each document is recorded under a typical heading. Leaf titles ought to be clear, succinct, and demonstrative of the record's substance. If it's not too much trouble, allude to segment 2.4 of this guide for extra data on leaf titles. In this segment, for gadget related records, each leaf title ought to be prefixed with "Gadget:"

5.1.3.5 Module 5

Human Factors entries for the mix item ought to be situated in e CTD area 5.3.5.4 Other Study Reports with joins from proper Module 3 records, and ought to incorporate the fitting human components record tag (e.g., HF-approval convention, HF-approval report, HF- approval other) to depict the archive's substance. Also, you may cross reference from Module 5 to Module 3 as pertinent.

5.1.4 CLINICAL TRAIL GUIDANCE DOCUMENTS

5.1.4.1 GENERAL GUIDANCE DOCUMENT

5.1.4.1.1 Establishment and Operation of Clinical Trial Data Monitoring Committees[20]

I. DMCs as well as other Classes under Monitoring

- Organizational Committee of Examination
- Guiding Panels for Clinical Testing
- Organization for Outcome Evaluation
- Location Surveillance
- Those with procurement procedure

II. Maintaining but Managing DMC

- Membership of commission
- Independent Report including Review Protection
- Setting up a Constitution that defines basic policies and procedures
- Possible DMC Obligations

III. DMC Guidelines and the criteria for reporting purposes

IV. That DMC Freedom

- Competitiveness of the a DMC Autonomous
- Benefit of a DMC Supporter Relationship
- Consequences of access to intermediate statistical information by sponsors
- Economists carried out the intermediate studies
- Affiliate Exposure for Informational Purposes to Intermediate Results.

5.1.4.1.2 Pharmacogenomics Data Submissions[21]

I. Submission Policy

- Universal concepts
- Basic applications of Pharmaceutical Creation and Marking Pharmacogenomics Details
- Advantages to advertisers including FDA of informal submission

II. Submission Of pharmacogenomics data

- Pharmacogenomics information delivery And during IND process
- Pharmacogenomics information application to the a current NDA, BLA, and substitute

- Submitting to the a generally established BLA and NDA
- Operation of Part 58 of 21 CFR
- Submission in Implementation Study Cooperative Demographic Results

III. Format and Content of a VGDs.

IV. Process for Submitting pharmacogenomics Data

5.1.4.1.3 Clinician Result Evaluates: Also used to endorse Branding Statements of medicinal product development[22]

I. Clinical Trial Design

- Implications of Specific Procedure
- Frequency for Evaluations
- Patient Length Study.
- Aspects of architecture with different endpoints.
- Clinical Trials Analysis Preparation that used a Generation immigrant Definition
- And use digital Professional tools, specific concerns.

II. Data Analysis

- Quantitative Specific Concerns
- Quantitative criteria with different target use
- Coaxial Edge routers Analysis Factors
- Numerical reasons of incomplete information at general practitioner
- Clinical Trials Findings Explanation

5.1.4.1.4 Collection of Race and Ethnicity data in Clinical Trials[23]

I. Collecting Race and Ethnicity Data in Clinical Trials

- Two-Question Format
- Self-Reporting
- Ethnicity
- Race
- Use of More Detailed Racial and Ethnic Categories
- Use of the term ―nonwhite‖.

II. **Presentation of Clinical Trial Race and Ethnicity data** It guide explains certain characteristics of ethnicity and race. As of May 2017, CBER both CDER would involve electronic submission of marketing applications. The e CTD is used by CBER and CDERas norm for their electronic software. The display of demographic information is identified in the ICH m4 e CTD guidelines whenever an electronic application is made.

5.1.4.2 INSTITUTIONAL REVIEW BOARDS (IRBS) AND INFORMED CONSENT GUIDANCE DOCUMENTS

5.1.4.2.1 Adverse event reporting to IRBS - Improving Human Subject Protection[24]

Detailing AEs to IRBs In Clinical Trials Of Drug And Biological Products Conducted Under IND Regulations

- Determine If an AE is an Unanticipated Problem that Needs to Be Reported
- Report Unanticipated Problems to IRBs.

1. Announcing AEs TO IRBs in Clinical Trials Of Devices Under The IDE Regulations

The investigational gadget exception (IDE) guidelines characterize an unforeseen unfavorable gadget impact (UADE) as "any genuine antagonistic impact on wellbeing or security or any perilous issue or demise brought about by, or related with, a gadget, if that impact, issue, or passing was not recently distinguished in nature, seriousness, or level of frequency in the investigational plan or application (counting a valuable arrangement or application), or some other unexpected significant issue related with a gadget that identifies with the rights, wellbeing, or government assistance of subjects".

UADEs should be accounted for by the clinical examiner to the support and the inspecting IRB, as portrayed beneath.

- For gadget contemplates, agents are needed to present a report of a UADE to the support and the inspecting IRB as quickly as time permits, yet in no occasion later than 10 working days after the specialist initially learns of the occasion
- Sponsors should quickly direct an assessment of a UADE and should report the consequences of the assessment to FDA, all inspecting IRBs, and taking an interest agents inside 10 working days after the support initially gets notice of the impact

5.1.4.2.2 Using a Centralized IRB Review Process in Multicenter Clinical Trials[25]

I. IRB Records - Documenting agreements and Procedures

A. International treaties Recording If an organization, the IRB, and a centralized IRB consent to engage in a consolidated evaluation mechanism for the IRB, the decision shouldbe recorded in an arrangement agreed by the parties. IRBs must report to a prosecutor as well as the institution on this intervention.

B. Registered Practices If a central IRB reviews an establishment and also an university's IRB, all IRBs would have established protocols in order to execute the unified IRB evaluation mechanism. IRB's.

5.1.4.2.3 Continuing review after clinical investigation approval[26]

- Requirements for Authorizing Analysis Throughout Continuation Analysis
- Method for Performing Continuation Examination
- Primary Issues to Remember Through Continuation Research
- Whether Accelerated Review Protocols Can Be Used for Continuation Research
- Increasing Review Pace
- Assessing the Approval Process of Original IRB Acceptance and Continuation Study Dates
- Explaining the Enabling Assessment of the IRB

5.1.4.2.4 IRB Exemption as well as change with Integrative Prosecutions Fully Matured concerning not much more than low disruption with laboratory animals[27]

IRB Exemption or Alteration of Informed Consent

Waiver of educated assent for certain FDA-managed insignificant danger clinical examinations will encourage specialists' capacity to lead contemplates that may contribute considerably to the advancement of items to analyze or treat sicknesses or conditions or address neglected clinical necessities. FDA means to reconsider its educated agree guidelines to add this waiver or adjustment under fitting human subject security shields tothe two existing exemptions from educated assent. forgoing the prerequisites to get educated assent when the IRB finds and reports that.

- Clinical examination will include close to a low interruption (as characterized in 21 CFR 50.3(k) or 56.102(i)) to subjects;

- Waiver or reevaluation will not contrarily influence the wellbeing and respect of subjects;
- Work commitment will not be for all intents and purposes conceivable without waiver or change;
- Where reasonable, genuine advantages will be given to subjects

Unique Health Investigation queries for concerns regarding applying the guidelines in this guideline for a particular clinical inquiry, supporters, inspectors and IRBs the approach the FDA - CDRH, CBER and CDER.

5.1.4.3 DRUGS AND BIOLOGICS GUIDANCE DOCUMENTS

5.1.4.3.1 Handling and retention of BA and BE Testing samples

Suggestions should be provided to test promoters and/or drug suppliers, contract testing organizations (CROs), site management organizations (SMOs), scientific investigators and impartial foreign entities concerning the protocol for treating reserved materials from of the related trials on bioavailability (BA) and bioequivalence (BE), as needed by 21 CFR 320.38 and 320.63.

I. Sampling Techniques

- **Single Container** – Is if test facility is supplied with a single container of both the research article and calibration curve, the test facility should extract from its provided in section an adequate number of a test article and reference standard for the purpose of performing the study; the remaining for each container will be kept as backup samples in the appropriate containers.
- **Multiple Containers** – When a testing facility is supplied with several containersof the test article or reference method, the testing site can randomly pick enough containers of the research item and comparison specification to conduct the study.
- **Unit Dose** – The residual unit doses in the scientific report and even in the standardcurve must be kept throughout the initial unit dose kit as backup specimens. It would also be unacceptable to include the research drugs in the package of the unitdose and then all the backup specimens in capacity and quality.
- **Blinded Study** –, That research supporter and/or drug maker must supply the research center with such a labeled collection of a test substance to comparison norm necessary can execute

a research even with separate, equivalent ranges sufficient to maintain that "five times amount".

II. Retention for Multiple Studies and Shipments

III. Quantity of Reserve Samples

IV. Responsibilities in Various Study Settings

- Needs to perform at CROs, colleges, clinics or offices for doctors,
- SMOs Experiments Concerning
- Willfully blind trials concerning SMO of chemo or therapeutic nodes
- Along with trials carried out by a supporter of a research and/or drug producer,
- In Laboratory BE Analysis

5.1.4.3.2 Clinical studies section of Labeling for Human Prescription drug and Biological products[27]

I. Recognizing trials for use in the chapter about Clinical Studies

- Research To be found in the Portion of Clinical Studies
- Research which should not be included in the Clinical Studies segment.

II. Describing Studies in the Clinical studies section

- Common concepts System requirement
- Discussing a Style of Research
- Outlining test results
- Providing proof for various outcome forms
- Implicit statements or marketing criteria and ads
- Going to update that Chapter about Drug Trials

5.1.4.3.3 Clinical trial enrichment techniques to facilitate the assessment of the efficacy of human medicines and biological products

I. Decreasing Variability

- Inspiring adhesion
- Reducing reactions to medication but random change.

II. Prognostic Enrichment Strategies — Identifying High-Risk Patients

- Undergo in Methods for Neurocognitive Enhancement
- Significant power Diagnostic Enhancement Techniques.

III. Predictive Enrichment — Identifying More-Responsive Patients

- Greater viability for performance
- Compensation partnership improved
- Statistical Optimization methods.

IV. Enrichment Study Design and Other Considerations

- General Considerations
- Populations to Study
- Type I Error Rate Control for Enriched Study Subpopulations
- Adaptive Enrichment
- Cautions in Interpretation.

V. Enrichment — Regulatory Issues

- The Decision to Use an Enrichment Strategy
- Study of Marker-Negative Patients
- Labeling

5.1.4.3.4 Exploratory IND Studies.[28]

Content of IND Submissions

A. Clinical Information

- Concepts with overall strategy for the inquiry
- Styles in study.

B. Chemistry, Manufacturing, and Controls Information

- Specific data for commodity nominee
- Technical analysis for product representatives.

C. Safety Program Designs Examples

- Pharmacokinetic profile or spectroscopy clinical trials

- Human development to research injections which are pharmaceutically appropriate
- Clinical studies of MOAs linked to effectiveness.

D. GLP Compliance.

5.1.4.3.5 Premarketing risk assessment[29]

I. Generating Risk Information during Clinical Trials

- Scale of a Protection Repository of Premarketing
- Issues to consider for creating a Protection Framework of Premarketing
- Trying to detect unexpected communications as part of the safety evaluation
- Quantitative Good Overall creation

II. Special Considerations for Risk Assessment

- Benefit evaluation throughout product creation
- Evaluation or criminalization of a risk of mistakes of medicine
- Addressing issues of protection throughout product production.

III. Data Analysis and Presentation

- Addressing adverse reactions to recognize signs of protection
- Perceptual or Even other Relations research
- Analysis of the dosage response as a link to value creation
- Information Pooling's role in risk assessment
- Use Collective Risk Mitigation Data
- Comprehensive determination of explanations for withdrawal from study
- Lengthy Join
- Relevant dimensions of the analysis of information

5.1.4.3.6 Safety reporting requirements for INDs and BE/BA studies

I. Review of Safety Information

II. Monitoring the safety Database and submitting IND Safety reports

- Assumed severe an unpredictable extreme reaction
- Some Outlets Results
- Enhanced incidence with alleged significant adverse events.

III. Other Safety Reporting Issues

- Different Agreements for Reports
- Guidebook for Investigators
- Exasperating Member states
- Collection by Investigator
- Advertised Narcotics Inquiries
- For the Institutional Review Boards Adverse Event Reporting
- Security Monitoring Period.

IV. Submitting an IND Safety Report

- Identity of Document Including Type
- Application
- Timeframe Monitoring.

V. Safety Reporting Requirements for BA and BE Studies

- Health Documentation Criteria for BE/BA Analysis
- Initiatives taken a Non-U.S. BE/BA The Sites

5.1.4.4 MEDICAL DEVICES GUIDANCE DOCUMENTS

5.1.4.4.1 Humanitarian Device Exemption (HDE) Program[30]

I. HUD Designations and HDE Applications

A HDE user basic step schedule and apply a HUD designation application to OOPD and obtain a HUD classification until sending an HDE petition to CDRH or CBER.

Referto 21 CFR 814.102(a) and the FDA "Humanitarian Use Device (HUD) Designations" instructions for even more detail on the planning and application of a HUD designation order.

II. FDA's Review of HDE Applications

Evaluation of HDE applications by the FDA have parallel, to a couple main differences, to evaluation of PMA apps. Any comparisons with the PMA curriculum involve.

- HDE modifications, supplements and documentation are normally subject to specifications similar with those for PMAs (although timeframes differ).
- HUDs is subjected to a 21 CFR part 820 quality system (QS) legislation, but HDE

implementations must provide adequate detailed information to allow the FDA to render a specifically known mostly on quality management used in the manufacture of a product.

A. Components needed for HDE Request and Concepts for filing examination

- The FDA must decide if the quality of the HDE submission makes it necessary for the comprehensive analysis to begin.
- The filing judgment of the FDA must not be focused on a substantive analysis of the facts and evidence throughout the HDE application.
- Analyses of HDE compliance filings. Within 30 calendar days from the date of receipt of a HDE submission, the FDA must inform that HDE claimant of itemized deductions.

B. FDA Review Actions for an HDE Application Department may take the following measures during the course of the investigation after an initial HDE application or HDE supplement is approved for filing and the FDA starts its comprehensive review:

- Authorization request;
- Insurable note;
- Huge letters of insufficiency;
- Never allowable document;
- Rejection purchase.

For initial HDE implementations and HDE replacements, the evaluation period is 75 days.

III. Evaluation of potential gain or uncertainty inside a framework for HDE

There is a potential advantage for HDE implementations in which there is reason for the FDA to correctly believe that the use of the device is likely to benefit patients. FDA analysis workers are prompted by the likely compensation decision support systems to discuss alternative value in terms of:

- Form of impact(s),
- Extent of benefit(s);
- Likelihood from one or even more asset(s) experienced by patients;
- Period of effect(s)

I. Person views

II. The viewpoints of the supportive person (e.g., relative or assistant).

IV. Post-Approval Requirements

A. IRB or Appropriate Local Committee Oversight and Approval

The owner of the HDE is not expected to apply to a FDA the contact details of the examining IRBs or suitable local committees. However, the HDE owner should, as neededin 21 CFR 814.126(b)(2), maintain copies of.

- The phone numbers and addresses of the hospitals to which HUD was delivered
- Interaction to IRBs evaluation;
- Any other details sought by an IRB or FDA examination.

B. Adverse Event Reporting Both adverse effects, whether suspected or not, must be reported and measured in compliance with the 21 CFR part 803 criteria for Medical Device Reporting. Device suppliers and consumer facilities are told to deliver to the FDA and the "IRB of record" (i.e. the IRB monitoring the use of HUD at the location where adverse condition happened) regarding the completion of the HDE.

C. HDE Supplement If an initial HDE request has been accepted by FDA, this same user must request an HDE replacement for evaluation / confirmation by the FDA until creatingan adjustment affecting the safety or likely benefit of the product.

D. HDE Periodic Reports In compliance with such an acceptance request under 21 CFR 814.126, you should send periodic reports for HDEs (b). Except where stated by the FDA, HDE periodic reports shall contain the following.

E. HUD Designation Re-Evaluation If another FDA is worried that the HUD classification can no long extend to the device based on the details found throughout the HDE regular reports, they can notify you for detailed details, re-evaluate and probably withdraw the HUD classification, and/or take away ones HDE certification.

V. Special Considerations for Devices Marketed Under an HDE

- Requirements for benefit
- The Annual Delivery Number (ADN)

- Clients' details
- Pediatric Patients or HDEs
- Analysis and acceptance of Health Treatment Use of HUDs
- Examination and consent for HUDs' clinical trials
- HUDs Crisis Use.

5.1.4.4.2 Factors that should be considered if allowing profit-Determination of risk inpremarket clearance of medical devices for De Novo designations

I. Factors FDA Considers in Making Benefit-Risk Determinations

- Evaluation of technologies 'advantages
- Evaluation of System Threats
- Additional considerations throughout the analysis of the possible benefits and risks of devices.

II. Examples of Benefit-Risk Determinations

- Theoretical Cases
- Descriptions based on the real assessments of FDA profit

I. Appendix A Combination with ISO 149711 of this Guidance

II. Appendix B Benefit-Risk Assessment Worksheet, Offer Goods Overview

III. Formative assessments for Theoretical Scenarios in Appendix C

5.1.4.4.3 Humanitarian Use Device (HUD) Designations

I. Contents of HUD Requests

- That Illness and Disorder Summary
- Development estimative
  - Therapeutic Devices
  - Diagnostic Devices
  - Devices Intended For Repeat or Multiple Use.
- Angel subset of a disorder or Non-Rare Illness
- Definition of the unit or theoretical rationale because of its planned usage
  - Device Description
  - Scientific Rationale

- Supporting Documentation

5.1.4.4.4 Gender, ethnicity, and race measurement and reporting-Specific results indrug testing of medical equipment[31]

I. Suggestions for Achieving Appropriate Enrollment

a) Prospective sex, sex, or ethnicity considered-Specific incongruities
b) Planning for Diverse Study Recruitment
c) Considerations for Study Follow-Up Visits.

II. Taking into consideration maturity, gender, and ethnic in research design, research review, and research interpretation of the results

A. Determining Gender, Racial, and National Subset Variability
B. Design research: guidelines for unique mathematical elements for categories
C. Performed experiments: Guidelines to Subcategory data acquisition
D. Gender, Race, and Ethnic interpretation-Specific data.

III. Suggestions for providing detailed statistics on gender, ethnicity, and sexuality in applications to the department and publishing in government records

A. Enlistment Demographics, Baseline Characteristics and Co-Morbidities

- IDE Stage
- Premarket Submission Stage
- Post market Submission Stage

B. Age-, Race-, and Ethnicity-Specific Outcomes (Safety Or Effectiveness, Or Probable Benefit For HDES

- Premarket Submission Stage
- Post-market Submission Stage.

5.1.4.4.5 General Principles of Software Validation[32]

I. Context for Software Validation

Requisites and specifications: For just a device and for its applications, a specification may be some necessity or expectation. Requirements reflect the client's specified or inferred desires, which can be commodity, negotiated, or regulatory, and the organizational specifications of even

an entity.

- Verifying and Validating
- IQ/OQ/PQ

- Production of applications as part of device architecture
- Software varies from hardware
- Advantages of software validation
- Design analysis.

II. Principles of Software Validation

- Specifications
- Fault Avoidance
- Length & commitment
- Product lifecycle technology
- Intends
- Protocols
- Confirmation for Applications following its Transition
- Documentation in verification
- Autonomy for analysis
- Versatility or Liability.

III. Activities and Tasks

- Life Cycle Operations in Applications
- Typical Activities that Support Validation

IV. Computerized Production Equipment and Consistency System Device Validation

- Proof for Validation
- Defined user specifications
- Away Applications and Automatic Appliances testing

5.1.4.4.6 Recognition of patient evidence to support approvals for medical products and Submissions.[33]

A. Conformity with GCP

- Declarations about the implementation of forensic inquiries
- Unique conditions regarding inquiries into in vitro diagnostic (IVD) instruments utilizing unused, counter biological specimen.

B. Supporting Information

- Names of agents and contact details of testing laboratories and places that investigator documents are stored.
- Credentials of prosecutor
- Definition of the services for study
- Detailed description of the investigative procedure and findings and, if needed, data that resides or additional background evidence
- Limited Knowledge about the unit
- Debate indicating how knowledge so information represent legitimate empirical data
- Overview as to how to receive information sheet
- Definition of rewards offered to participating subjects.

C. Waivers

- Information needed and delivery of a leisure facilities
- Global health results of exemption demands.

D. Records

E. Implementation

5.1.4.5 MANUFACTURING REQUIREMENTS FOR INVESTIGATIONAL PRODUCTS GUIDANCE DOCUMENTS[34]

5.1.4.5.1 Design Control Guidance for medical device manufacturers

Healthcare system architectures, and the development of the related supply chains. The guideline refers to innovative designs and also to updates or upgrades in new systems of products.

Section A. General

- That supplier of any Class III or Class II equipment and that of the Class I equipment referred to in point (a)(2) of this Section shall develop and maintain protocols for system development of the tools to ensure that the range of design specifications are met.

Section B. Design and Development Planning

- That producer shall draw up and retain plans identifying or referring the operations of design and manufacturing and specifying the accountability for execution.
- Proposals shall define and explain the applications for the various classes or events and provide input into the design and development process, or that results in it.
- When engineering and building progresses, proposals are updated, revised or authorized.

Section C. Design Input

- Each manufacturer shall develop and retain protocols to ensure that the equipment- related specification specifications are acceptable and address the expected usage of the equipment.
- The protocols provide a method to comply with missing, unclear or contradictory specifications. The criteria for design feedback are reported and reviewed and accepted by selected entities.
- Its certification shall be notified, such as the date and signatures of the item(s) authorizing specifications.

Section D. Design Output

- Which designer develop and implement protocols for identifying and reporting the output of the design in ways to allow an adequate assessment of conformity with the specifications of the design input.
- Proposed definition procedures include or apply to approval requirements and shall ensure that all layout outs are defined which are essential for the proper functionality of the system.
- The performance of the project shall be registered, checked or authorized without publication.

Section E. Design Review

- That supplier shall establish and retain protocols to ensure that systematic, recorded evaluations of the effects of the design are prepared and carried out at the required stages of

the construction production of the device.

- The findings of a design analysis shall be recorded in the design history log, containing the specification of design, the period, as well as the member(s) conducting the analysis (the DHF).

Section F. Design Verification

- Can supplier must develop and retain protocols to validate the specification of the product.
- Design testing shall ensure that the performance of the design satisfies the specifications of the design input.
- The Design History File shall record the results of the system testing, such as the description of the project, the transverse electric), the period and the person(s) conducting the verification.

Section G. Design Validation

- Designing verification shall be carried out on early manufacturing facilities, loads and loads as well as lots, or derivatives thereof, under specified operating conditions.
- Evaluation of the specification helps maintain that the systems meet with specified consumer requirements and planned applications, which shall involve evaluation of the manufacturing facilities in circumstances of real or simulation usage.
- Affirmation of the specification must involve program testing and risk assessment,

Section H. Design Transfer

- Protocols shall be developed and retained by each company to make sure that the configuration of the unit is properly transformed into production requirements.

Section I. Design Changes

- Increasing designer develop and implement protocols to defining, reporting, validating or, when applicable, checking, evaluating and authorizing adjustments to the specification prior to the introduction.

Section J. Design History File (DHF)

- A DHF normally contains or refer the documents required to indicate that the project was

drawn up in compliance with the authorized proposed design as well as the provisions of this section.

5.1.4.5.2 INDS for stage 2 and stage 3 examinations science, assembling and controls data[35]

I. **General Principles** This direction gives proposals on CMC wellbeing data and the restricted confirming data that ought to be submitted to help stage 2 and stage 3 examinations.

1. CMC Safety Information

Regarding the appropriate utilization of the medication, CMC wellbeing subtleties should be submitted. To assess if a clinical grasp on the IND is justified, the FDA looks at the wellbeing data. In stage 2 and stage 3, the CMC security issues depicted in the commencement stage rules are also significant.

CMC alterations all through the IND cycle that can influence wellbeing to incorporate, yet are not restricted to, a change in.

- This same combined course used to create the medication substance — content move in one of the means of bond development — change in a fluid utilized in the last response as well as crystallization stage — change bringing about a particular pollutant profile
- The creation strategy that may impact the consistency of a matured or normally determined medication item (plant, creature, or human)
- Original story (for example plant-to-creature, species, halfway utilized) or identity for a substance acquired from either a characteristic wellspring of a medication.
- Fermentation-produced species as well as the strain of microorganism for a medication substance
- Certain components of prerequisites
- The drug substance or dynamic drug fixings contraception procedure
- Its organization course
- Formulation and additionally restorative portion kind of the result of a medication
- A creation line for the medication substance which can impact the nature of the item
- The alleviation structure for the medication item holder that can impact the nature of the item (e.g., metering capacity, portion conveyance).

2. **Proving Information** Corroborating proof is utilized to decide the scientific consistency of the prescription fixing and item part utilized in the clinical examinations to ensure that exact and interpretable outcomes are gathered from the clinical examinations and to approve the quality and wellbeing of the clinical materials utilized in the previous periods of the examination.

II. Phase 2 Studies In order to keep the continued health of the client registered in these studies, the CMC info supplied to sustain the phase 2 studies will focus on extra CMC data.

A. Drug Substance

- General Information
- Manufacture
- Manufacturers
- Description of Manufacturing Process and Process Controls
- Control of Materials
- Controls of Critical Steps and Intermediates
- Control of Drug Substance
- Reference Standards or Materials
- Container Closure System
- Stability

B. Drug Product

- Description and Composition of the Drug Product
- Manufacture
  - Manufacturers
  - Batch Formula
  - Description of Manufacturing Process and Process Controls
- Control of Excipients
- Control of Drug Product
- Container Closure System
- Stability

III. Phase 3 Studies

All through phase 3 studies, CMC continues to develop in comparison to clinical trials. The safety information provided by the CMC in support of the phase 3 studies should concentrate on the data required to maintain the sustained safety of the patient registered in such studies.

A. Drug Substance

- General Information
- Manufacturer
- Manufacturers
- Description of Manufacturing Process and Process Controls
- Control of Materials
- Controls of Critical Steps and Intermediates
- Characterization
- Control of Drug Substance.
- Reference Standards or Materials
- Container Closure System
- Stability

B. Drug Product

- Description and Composition of the Drug Product
- Manufacture
  - Manufacturers
  - Batch Formula
  - Description of Manufacturing Process and Process Controls
- Control of Excipients
- Control of Drug Product
- Container Closure System
- Stability

IV. Fake treatment: If a fake treatment is to be utilized in the main second, the rundown of the organization, creation, and control of fake treatment given during stage 1 ought to be adjusted or provided for stage 2 or potentially stage 3.

V. **Naming:** Between stage 2 and stage 3, updates of the data introduced for the inception stage ought to be submitted in the light of data adjustments.

VI. **Environmental Assessments** Notifications on the information already received or whether the argument for prior normative exemption had modified should be made available in the Phase 2 and phase3 data updates.

5.1.4.5.2 CGMP for Phase 1 Investigational Drugs

I. Recommended CGMP for Phase 1 Investigational Drugs

Manufacturers should develop production controls based on defined production setting hazards that confirm good science and QC principles.

- **Personnel** In order to encourage each individual to fulfill their assigned function, all workers must have the expertise, experience, and training or some variation.
- **QC Function** A documented schedule that explains the position and obligations of QC roles must be defined by any producer.
- **Facility and Equipment** Sufficient maintenance activities and facilities for the expected task should be given for every laboratory used in the development of phase 1 interventional drugs.
- **Control of Components and Containers and Closures** Components must be monitored (e.g. isolated, labeled) before products are being inspected or evaluated, if required, and published to production use.
- **Manufacturing and Records** Documented packaging and process control processes that account for the following records will be followed in the manufacturing of preliminary experimental drugs.

Laboratory Controls

Testing Good scientific (e.g., descriptive, adaptive, and precise) laboratory tests used in production must be acceptable and reliable for the stated purpose.

Stability A control law utilizing qualitative data of the Phase 1 drug combination should be initiated to track the soundness of the Preliminary drug combination and during clinical study.

- **Packaging, Labeling and Distributing** To shield this from modification, infection, and disruption throughout packaging, handling, and delivery, the phase 1 experimental product will be appropriately wrapped.

- **Recordkeeping** Manufacturing companies must maintain complete documentation of a value including execution of the production processes, as shown in the subsequent paragraph, include but are not restricted to.

- Equipment support and adjustment
- Manufacturing records and related scientific test records
- Distribution records QC capacities
- Component records
- Deviations and examinations
- Complaints.

II. Special Manufacturing Situations

A. Multi-Product Facilities Inside an area or space apart from unrelated operations, we suggest that you produce an only phase 1 experimental product at a certain particular time.

B. Materials for biology including synthetic biology

- Management- Factors
- Stem Cells and Cell Treatment
- under Imply Entity Regulation.

C. Sterile Products/Aseptically Processed Products Since product sterility is a vital component of the protection of human subjects, special care should be taken for investigational drugs expected to be sterile in phase 1.

5.1.5 REGULATORY CHALLENGES AND SUBMISSION OF COMBINATION PRODUCTS AS PER USFDA GUIDELINES[36]

5.1.5.1 Current regulations, challenges and global trends

Combination products are only a big market, including the increasingly developing FDA, which draws considerable global attention. Combination products have cross-validity witha range of uses covering high-profile types of illnesses, medicines and biologics. There is no limit to these products' reach and expansion in the US and emerging markets. The OCPalso provides the authority of the main body (CBER, CDER, CDRH) to determine the material subject to the primary mode of operation. Nevertheless, the related policies of management strategies may

prove difficult with rapidly emerging technological breakthroughs, particularly competing product categories delegated to the primary medical center's authority.

5.1.5.2 Challenges of combination products while many of the issues involved with the production and delivery of hybrid medications only affect specific therapies, owing to the increasingly complex nature of these products, potential risks can be compounded. The following include common issues:

5.1.5.2.1 US Regulatory Landscapes Variable and ever-changing from around world; it may be possible to feel completely informed about current legislation and guidelines, especially on combination items. Indeed, West's consumer survey found that the competitive regulatory environment is always the toughest hurdle for pharmaceutical firms to encounter specific hybrid drugs.

Even before putting a hybrid product into the market, concepts of terms must be known to maintain that show's is on the same level. Furthermore, various regions/countries has specific requirements and regulatory submission procedures.

The combined drugs of today also indicate that the system and the drug(s) must be produced in tandem. This relates to regulatory specifications as regards the mechanism foridentifying the primary mode of action of the product (PMOA) which serves to define its regulatory and product creation structure.

5.1.5.2.1 Device Challenges, This can contribute to damaged product functionality, including arising from the disconnection of drugs and devices or the creation of packaging. A patient obtaining a drug that is quick and simple relies toward a significant degree on the durability or robustness as a launch platform, in addition to all other packaging components. Testing used in detecting and solving system issues must require thorough testing of biodiversity factors. The key concern for hybrid items is how a system and a drug interact. In order to clearly and accurately show the impacts of one factor but at the other, drug and device manufacturers have to work very closely together soon as possible in the production process.

5.1.5.3 Useful Challenges and Opportunities The need to control blend items has pushed the practically autonomous part habitats of the FDA to team up with one another in headings that couldn't be considered typical ten years prior. Such an issue is exacerbated by the way that, in contrast to meds and gadgets themselves, the level of headway in uniting innovation is a different development in any field in particular.

The Office of Combination Items (OCP) of the Department gives help with this regard, yet the Office is additionally generally youthful and has restricted staff. Presently coordinated by Joanne R. Less, Ph.D., previously Associate Director of Clinical Research at CDRH, OCP has a difficult mission. The different business sectors it addresses have very various perspectives and objectives, preparing for work will assess its choices.

Allocate evaluation duties to mixed goods.

- Help make sure that the pre - market analysis is accurate and comprehensive.
- Create clear and effective control of the sub industry.
- Perform conflict settlement (timeliness versus substance).
- Guidelines, contracts, and procedures to study and amend.
- Compile Congressional studies.
- Represent as just a platform to evaluate workers for supporters.

Since OCP is poorly equipped, sector has the potential to fill in holes through aiding it stimulate ideas for novel regulations; with contributing in research; by exchanging regulatory, science and practical knowledge; so by providing feedback of OCP proposals.

SUMMARY

A combination product is a combination of multiple medical products, including drugs, devices, and biological products. These products can be single entities, co- packaged, or cross-labeled. Premarketing pathways include device-led combination products, such as IV bags, syringes, injectors, oral administration devices, and nasal sprays. The Center for Drug Evaluation and Research (CDER) leads premarket review and regulation of these products. The International Council for Harmonization (ICH) provides guidance on quality aspects, including reproducibility of dose delivery, stability testing, and functionality testing. The FDA issued CGMP requirements

for combination products in January 2013.

The Office of Combination Products (OCP) provides comprehensive guidance on product classification, jurisdiction, and combination products. The FDA's three Centers (CBER, CDER, and CDRH) also offer product-specific guidance. Key documents include Principles of Premarket Pathways for Combination Products, Requesting FDA Feedback on Combination Products, Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors, Bridging for Drug-Device and Biologic-Device Combination Products, Post marketing Safety Reporting for Combination Products, Human Factors Studies and Related Clinical Study Considerations, Pre-Request for Designation (Pre-RFD), Manufacturing and Safety (cGMP), and Application User Fees. These guidelines help navigate the complexities of combination products, ensuring safety and efficacy in the market.

ACKNOWLEDGEMENT

The secret of success is undaunted ardor, motivation, dedication, confidence on self, and above all the blessing of God. I bow in reverence to the Almighty for best owing upon me all his kindness that has helped me throughout the journey of my life. Success is an outcome of collaborated efforts aimed that achieving different goals. I hereby take this opportunity to acknowledge all those who have helped me in the completion of this dissertation work.

With a deep sense of gratitude and veneration, I express my profound sense of appreciation and love to my beloved and Family members, for providing me love like heaven’s caring arms both materially and emotionally. Their fundamental truths which exist as divine power can lift one from confusion, misery, melancholy, and failure, and guide one’s true place.

I am proud to dedicate my deep sense of gratitude to the founder, (Late) **Dr. J. K. K. MUNIRAJAH, M. TECH., (BOLTON),** for providing us with a historical institution to study.

My sincere thanks and respectful regards to our reverent **Smt. VASANTHA KUMARI MUNIRAJAH**, Managing Trustee, Annai JKK Sampoorani Ammal Charitable Trust, and **Mr. J. K. M. JAYAPRAKASH**., Correspondent, JKK Munirajah Educational Institutions, Komarapalayam for their blessings, encouragement, and support at all times.

A work of this dimension cannot be produced without the help of many people. Among the foremost, I desire to take this opportunity to express my deepest thanks, heartfelt, indebtedness, and respectful Guide to **Dr. N. SENTHILKUMAR**, **M. PHARM, Ph. D.,** Principal, Department of Pharmaceutical Regulatory Affair, JKKMMRF's Annai JKK Sampoorani Ammal College of Pharmacy, Komarapalayam, for providing much of suggestions, encouragements during the project. Without his critical evaluation and deep- rooted knowledge this thesis would now have become a reality. His parental care and patience will always be remembered.

My immense privilege and profound gratitude to **Dr. B. SENTHILKUMAR, M.PHARM., PH.D.,** Head of The Department of Pharmaceutical Regulatory Affairs, JKKMMRF's Annai JKK Sampoorani Ammal College of Pharmacy, Komarapalayam, for wholehearted support and guidance, helped me to complete this project work in a very successful manner.

I express my heartfelt thanks to **Mr. R. VIJAYAMIRTHARAJ, M.PHARM.,** Vice Principal, JKKMMRF's Annai JKK Sampoorani Ammal College of Pharmacy, Komarapalayam, for his valuable suggestions during this work.

My sincere thanks to **Dr. S.Chandra, M.Pharm., Ph.D**., Professor and Head in the Department of Pharmaceutics, **Dr. K C. Arul Prakasam, M.Pharm., Ph.D**., Professor and Head in the Department of Pharmacy Practice, **Mr. K. Jaganathan, M.Pharm.,** Associate Professor, **Mr. A.Sheik Alisha, M.Pharm**, Assistant Professor, Mr. **R.Neelamegarajan, M.Pharm,** Assistant Professor in the Department of Pharmaceutical Regulatory Affairs, **Dr. V.Suresh**, **M.Pharm., Ph.D**., Professor and Head in the Department of Pharmacology **Dr. Kannan, M.Pharm., Ph.D.,** Associate Professor in the Department of Pharmacology for their valuable suggestions and support during my project work.

I would also like to thank the Chief Librarian, Mrs. **P. Loganandhi., M.Com., MLISc,** and supporting staff, **Mrs. M. Megala,** at JKKMMRF'S Annai JKK Sampoorani Ammal College of Pharmacy, Komarapalayam.

I express my heartfelt thanks to other Department Professor and Head, for their help and valuable support during this work. I would like to thank my friends and classmates for their help and valuable support in a time of need.

I would like to thank the non-teaching staff **Mrs. M. Kasthuri** and other Non- teaching staff in the Department of Pharmaceutical Chemistry for their support during this work.

My humble thanks to all the mentors, well-wishers, and near and dear ones who helped me in their own way.

CONCLUSION

The main drawback of the regulatory authority in drug-device, biologic-device of the combination products are not given the proper regulatory requirements in FDA, Its major problems related to the development and distribution of combination products and makingthe regulatory documents it is complicated to make the submission of combination products. The possible complications can be exacerbated due to the highly dynamic design of these products. we need individual regulatory requirements of the drug-device, device-biological, in each category of the combination products documents. for the regulatory writer, it is difficult to write the documents, and there are a lot of the guidelines is listed onthe FDA site. we need an individual guideline of the drug-device, biological - device of therequirement in combination products.

The development of innovative biomaterials and technologies has led to the research and development of combination products, which are defined and designated by regulatory authorities. The goal is to ensure safety and efficacy through a systematic approach focusing on design rationale, preclinical evaluation, and clinical evaluation. However, challenges arise due to controversial MOAs and different definitions in different countries. Advanced regulatory evaluation systems and post-market surveillance systems are needed for these complex products. Combination products are rapidly growing due to drug and biologic therapies innovations and delivery system design. This market category has led to increased adoption of medical devices, increased complexity, and increased product experience and risk awareness.

REFERENCE

1. Commissioner, O. of the (2019). Combination Product Definition Combination Product Types. FDA. [online] Available at: https://www.fda.gov/combination-products/about-combination-products/combination-product-definition-combination-product-types.

2. https://www.coherentmarketinsights.com, C.M.I. (n.d.). Drug-Device Combination Products Market Size, Trends, Shares, Insights, Forecast - Coherent market insights. [online] www.coherentmarketinsights.com. Available at: https://www.coherentmarketinsights.com/market-insight/drug-device-combination- products-market-3919.
3. Commissioner, O. of the (2019). Combination Product Definition Combination Product Types. FDA. [online] Available at: https://www.fda.gov/combination-products/about-combination-products/combination-product-definition-combination-product-types.
4. Miller, K. (n.d.). History of Combination Products: Past, Present & Future Part 1. [online] Available at: https://www.pilgrimquality.com/blog/combination-products-part-1/#:~:text=combination%20product%20types
5. Commissioner, O. of the (2021). Office of Combination Products. [online] FDA. Available at: https://www.fda.gov/about-fda/office-clinical-policy-and-programs/office- combination-products#:~:text=The%20FDA%20Office%20of%20Combination
6. www.meddeviceonline.com. (n.d.). How To Determine A Combination Product's Primary Mode of Action (PMOA). [online] Available at: https://www.meddeviceonline.com/doc/how-to-determine-a-combination-product-s- primary-mode-of-action-pmoa-0001
7. Commissioner, O. of the (2020). How to Prepare a Pre-Request for Designation (Pre-RFD). [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/how- prepare-pre-request-designation-pre-rfd
8. Commissioner, O. of the (2019). How to Write a Request for Designation (RFD). [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/how-write- request-designation-rfd
9. Office of the Commissioner (2019). Early Development Considerations for Innovative Combination Products. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/early-development-considerations-innovative-combination-products
10. Guidance for Industry and FDA Staff: Application User Fees for Combination Products. (2005). [online] . Available at: https://www.fda.gov/media/76413/download
11. Commissioner, O. of the (2020). Glass Syringes for Delivering Drug and Biological

Products: Technical Information to Supplement International rganization for Standardization (ISO) Standard 11040-4. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance- documents/glass-syringes-delivering-drug-and-biological-products-technical- information-supplement.

12. Commissioner, O. of the (2020). Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted under a BLA, NDA or ANDA. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory- information/search-fda-guidance-documents/technical-considerations-demonstrating- reliability-emergency-use-injectors-submitted-under-bla-nda
13. Commissioner, O. of the (2020). Principles of Premarket Pathways for Combination Products. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/principles-premarket-pathways-combination-products
14. Research, C. for D.E. and (2020). Bridging for Drug-Device and Biologic-Device Combination Products. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bridging- drug-device-and-biologic-device-combination-products.
15. Commissioner, O. of the (2020). Requesting FDA Feedback on Combination Products. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requesting- fda-feedback-combination-products
16. Commissioner, O. of the (2020). Submissions for Postapproval Modifications to a Combination Product Approved Under a BLA, NDA, or PMA. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search- fda-guidance-documents/submissions-postapproval-modifications-combination-product- approved-under-bla-nda-or-pma
17. Research, C. for D.E. and (2020). Current Good Manufacturing Practice Requirements for Combination Products. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current- good-manufacturing-practice-requirements-combination-products
18. Commissioner, O. of the (2019). Postmarketing Safety Reporting for Combination Products. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-

information/search-fda-guidance- documents/postmarketing-safety-reporting-combination-products

19. Electronic Common Technical Document (eCTD) v4.0 TECHNICALCONFORMANCE GUIDE Guidance for Industry Providing Regulatory Submissions in Electronic Format - Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications. (2021). [online]. Available at: https://www.fda.gov/media/135573/download
20. Research, C. for B.E. and (2020). Establishment and Operation of Clinical Trial Data Monitoring Committees. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance- documents/establishment-and-operation-clinical-trial-data-monitoring-committees
21. Research, C. for D.E. and (2020). Pharmacogenomic Data Submissions — Companion Guidance. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacogenomic-data-submissions-companion-guidance
22. Research, C. for D.E. and (2019). Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product- development-support-labeling-claims.
23. Commissioner, O. of the (2019). Collection of Race and Ethnicity Data in Clinical Trials. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/collection- race-and-ethnicity-data-clinical-trials
24. Commissioner, O. of the (2019). Adverse Event Reporting to IRBs — Improving Human Subject Protection. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/adverse- event-reporting-irbs-improving-human-subject-protection.
25. Commissioner, O. of the (2020). Using a Centralized IRB Review Process in Multicenter Clinical Trials. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/using-

centralized-irb-review-process-multicenter-clinical-trials

26. Commissioner, O. of the (2020). IRB Continuing Review After Clinical Investigation Approval. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/irb- continuing-review-after-clinical-investigation-approval
27. Research, C. for D.E. and (2020). Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products — Content and Format. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory- information/search-fda-guidance-documents/clinical-studies-section-labeling-human- prescription-drug-and-biological-products-content-and-format
28. Research, C. for D.E. and (2019). Exploratory IND Studies. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search- fda-guidance-documents/exploratory-ind-studies
29. Research, C. for D.E. and (2020). Premarketing Risk Assessment. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory- information/search- fda-guidance-documents/premarketing-risk-assessment
30. Health, C. for D. and R. (2019). Humanitarian Device Exemption (HDE) Program. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance- documents/humanitarian-device-exemption-hde-program
31. Health, C. for D. and R. (2019). Evaluation and Reporting of Age-, Race-, and Ethnicity-Specific Data in Medical Device Clinical Studies. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search- fda-guidance-documents/evaluation-and-reporting-age-race-and-ethnicity-specific-data- medical-device-clinical-studies
32. Health, C. for D. and R. (2020). General Principles of Software Validation. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/general-principles-software-validation
33. Health, C. for D. and R. (2020). Acceptance of Clinical Data to Support Medical Device Applications and Submissions: Frequently Asked Questions. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search- fda-

guidance-documents/acceptance-clinical-data-support-medical-device-applications- and-submissions-frequently-asked

34. Research, C. for D.E. and (2020). Current Good Manufacturing Practice for Phase 1 Investigational Drugs. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current- good-manufacturing-practice-phase-1-investigational-drugs
35. Research, C. for D.E. and (2020). INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information. [online] U.S. Food and Drug Administration. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/inds-phase-2-and-phase-3-studies-chemistry-manufacturing-and-controls-information
36. Drug Development and Delivery. (2020). COMBINATION PRODUCTS - Development Challenges & Solutions. [online] Available at: https://drug-dev.com/combination- products-development-challenges-solutions/#:~:text=When%20assessing%20challenges%20that%20impact